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A  COMPARATIVE  STUDY  OF  EFFICACY  OF  CONTINUOUS  VERSUS  
INTERMITTENT  IRON  THERAPY  FOR  THE  TREATMENT  OF  IRON  
DEFICIENCY  ANEMIA  IN  CHILDREN  OF  AGE  GROUP  6  MONTHS  TO  5  
YEARS. 
Dr. C. Krishnakumar MD ( Peds ) Post Graduate Student 
Aim and Objective: 
To  study  the  outcome  of  Iron  Deficiency  Anemia  by  measuring  the  changes  
in  Hemoglobin  concentration  in  Continuous  versus  Intermittent  iron  therapy  in  
children  of  age  6  months  to  5  years  over  a  period  of  12  weeks  intervention  and to 
study the improvement in other hematological parameters like Hematocrit, MCV and 
compliance and adverse effect profile in both groups. 
Methods and materials: 
 140 children with iron deficiency anemia fitting into the inclusion criteria were 
enrolled. Randomized into intermittent n = 70 (biweekly) and daily iron supplementation 
group ( n = 70 ) and started on 3mg/kg of elemental iron in both groups. Followed at 3-5 
days for evaluating reticulocytosis, at 4 weeks at assess rise in hemoglobin and after 12 
weeks for reassessing all the hematological parameters done initially and adverse effect 
profiles. 
Observation and results: 
 Out of the 140 children, 68 in intermittent group and 65 in daily supplementation 
group were able to complete the study. Both the intermittent and daily iron supplementation 
group showed similar response to iron therapy in terms of  increase in Hemoglobin, 
Hematocrit and MCV. But the daily supplementation group showed significant increase in 
serum ferritin levels ( p < 0.001 ) as compared to intermittent iron supplementation group. 
However the compliance and adverse effects were lower in intermittent iron therapy 
group statistically significant than daily iron supplemtation group. 
Conclusion: 
 From the study, it was concluded that intermittent iron therapy is as effective as 
daily iron therapy in improving anemia in children of age 6 months to 5 years with 
improved drug compliance and lesser adverse effects. 
 
   A  COMPARATIVE  STUDY  OF  EFFICACY  OF  
CONTINUOUS  VERSUS  INTERMITTENT  IRON  THERAPY  FOR  
THE  TREATMENT  OF  IRON  DEFICIENCY  ANEMIA  IN  
CHILDREN  OF  AGE  GROUP  6  MONTHS  TO  5  YEARS. 
INTRODUCTION   
Anemia  is  one  of  the  major  public  health  issues  in  the  developing  
countries.  Despite  being  the  most  abundant  trace  element  on  the  earth’s  
crust,  its  relative  insoluble   nature  and  poor  bioavailability  makes  iron  
deficiency  anemia  as  one  of  the  most  prevalent  nutritional  deficiency  
disorder.    
In  spite  of  sustained  efforts  to  reduce  the  burden  of  nutritional  
disorders,  iron  deficiency  anemia  is  still  highly  prevalent  in  many  parts  
of  the  world1.  Around  the  world,  over  two  billion  people  i.e.,  about  
30%  of  the  total  population  of  the  world   still  remain  anemic.  The  major  
cause  being  iron  deficiency.  In  under  developed  regions,  this  scenario  is  
further  complicated   by  infectious  diseases.   
Worldwide,  47.4%  of  children  between  0  to  5  years  of  age  are  
anemic,  with  the  burden  being  greatest  in  low  and  middle  income  
countries.  More  than  50%  of  the  total  cases  of  anemia  were  attributed  to  
iron  deficiency.2  The  prevalence  of  Iron  deficiency  varies  between  
locations  but  is  estimated  by  the  World  Health  Organization   to  be  2.5  
times  higher  than  that  of  Iron  deficiency  anemia  in  most  places.3 
Iron  deficiency  is  one  major   public  health  condition  that  is  
emerging  onto  an  epidemic  proportion.  It  causes  more  morbidity  than  
any  other  condition.  Since  most  of  the  early  manifestations  of  iron  
deficiency  are  subtle,  iron  deficiency  imparts  its  heaviest  overall  toll  in  
terms  of   morbidity,  early  deaths  and  economic  losses.    
Invisible,  yet  ubiquitous  in  many  developing  countries,  the  true  
toll  of  iron  deficiency  and  anemia  lies  hidden  in  the  statistics  of  overall  
death  rates,  maternal  hemorrhages,  reduced  school  performance  and  
lowered  productivity.  The  health  consequences  are  stealthy  but  
devastating,  invisibly  eroding  the  development  potential  of  individuals,  
societies  and  national  economies. 
Children  are  at  particular  risk  of  Iron  deficiency  because  of  rapid  
growth  with  expanding  erythroid  mass  and  high  tissue  iron  requirements 
4. In  infants,  antenatal  and  perinatal  factors  can  influence  iron  status.  
Major  risk  factors  for  iron  deficiency  anemia  in  young  children  are  low  
birth  weight  and  preterm  delivery  where  the  body  iron  stores  are  limited. 
The  major  cause  for  the  very  high  prevalence  of  iron  deficiency  
anemia  are  due  to   low  dietary  iron  intake  and  the  poor  bioavailability  
of  the  ingested  iron.  Prolonged  milk  feeding  and  improper  
complementary  feedings  are  also  associated  with  Iron  deficiency,  Iron  
deficiency  anemia,  and  other  micronutrient  deficiencies 5. 
Causes  and  epidemiology  of  anemia  in  2  to  5  year  olds  appear  to  
differ  from  those  in  infants.  Children  2  to  5  years  of  age  are  more  
likely  to  be  ambulant  and  where  sanitation  is  poor,  can  acquire  
hookworm  infection,  which  can  result  in  Iron  deficiency.  The  burden  of  
anemia  from  malaria  may  also  decline  after  infancy. 
Our  national  surveys  (fig.1)  show  the  prevalence  of  anemia  at  12  
to  23  and  48  to  59  months  is,  83.0%  and  53.0%   respectively.  This  is  
similar  to  other  developing  countries  with,  69.1%  and  38.2%  in  Ethiopia,   
72.7%  and  42.0%  in  Malawi,  70.6%  and  20.7%  in  Nepal,  and  71.5%  
and  45.6%  in  Zimbabwe6. 
In  Indian  scenario,  the  percentage  of  male  and  female  children  (6-
59  months)  with  any  type  of  anemia  was  reported  as  69%  and  69.9%  
respectively,  severe  anemia  was  reported  for  3.2  %  male  children  and  
2.7%  female  children.  Anemia  was  more  prevalent  in  rural  areas  (71.5%)  
than  Urban  areas  (63%).   
Maternal  education  status  plays  an  important  role  in  the  nutritional  
status  of  the  child.  This  can  be  inferred  from  the  data  showing  
significantly  low  prevalence  of  anemia  in  children  of  mothers  with  
atleast  12 years  of  education  (55.4  %),  than  with  uneducated  mothers,  
where  the  prevalence  is  as  high  as  74.5%.  This  highlights  the  
importance  of  female  education  in  alleviating  the  burden  of  anemia. 
Economic  status  of  the  family  also  plays  a  major  role  in  
determining  the  nutritional  status  of  the  child.  This  fact  is  supported  by  
numerous  nutritional  survey  results.   
National  Family  Health  Survey  3  (2005-06),  reveals  76.4%  of  
children  (6-59  months)  in  the  lowest  wealth  index  are  suffering  from  
anemia  whereas  56.2%  children  of  the  highest  wealth  index  are  suffering  
from  anemia.  This  is  indicative  of  the  reality  that  affluence  alone  cannot  
rule  out  anemia  among  children.   
Children  are  particularly  vulnerable  for  iron  deficiency  anemia.  
Iron  deficiency  in  children  may  have  functional  consequences  beyond  
anemia.  These  include  impaired  motor  and  cognitive  development  and  
physical  growth3.  Iron  supplementation  has  been  thought  to  improve  
these  outcomes,8  but  some  impairment  may  be  irreversible9. Conversely,  
there  are  concerns  that  iron  may  produce  adverse  effects,  including  

















Iron  supplementation  is  considered  a  standard  approach  for  
treatment  and  prevention  of  Iron  deficiency  anemia11.  Supplementation  
programs  for  other  micronutrients,  such  as  vitamin  A  are  more  
successful  partially  because  there  are  few  side  effects  and  unlike  iron,  
daily  supplementation  is  not  necessary.   
Figure 1: Geographical distribution of Iron deficiency Anemia. (Source NFHS 3) 
However,  few  studies  have  reported  that  in  anemic  rats,  the  
supplementation  of  iron  twice  a  week  was  found  to  produce  comparable  
results  as  with  daily  iron  supplementation.   The  theoretical  explanation  
would  be  that  daily  supplementation  of  iron  leads  to  a  strongly  reduced  
absorption  several  days  after  initiation,  whereas  with  intermittent  
supplementation  the  level  of  absorption  would  remain  much  higher. 
Ideally,  supplementation  should  achieve  maximal  absorption  with  
minimal  side  effects.  As  a  public  health  measure WHO  recommended  
that     all  preschool-aged  children  should  receive  a  course  of  daily  iron  
supplementation  where  the  baseline  prevalence  of  anemia  is  >40%7. 
Intermittent  treatment  with  oral  iron  preparations  in  preschool  and  
school  aged  children  has  recently  been  evaluated  by  a  systematic  review,  
which  found  that  intermittent  iron  was  effective  in  reducing  anemia,  
although  less  so  than  daily  iron12.  On  the  basis  of  this  analysis,  WHO  
revised  the  guidelines  recommending  intermittent  iron  for  prevention  of  
anemia  in  children14. However  these  studies  did  not  include  a  comparison  
of  daily  iron  with  control. 
  From  the  public  health  point  of  view,  intermittent  dose  of  iron  
preparation  seems  to  be  more  convenient  when  compared  to  daily  
dosing.  Moreover,  it  is  economic,  safer  in  terms  of  avoiding  constant  
excess  iron  in  the  gastrointestinal  tract  and  offer  greater  coverage  for  the  























AIM  AND  OBJECTIVES 
 
AIM: 
To  study  the  outcome  of  Iron  Deficiency  Anemia  by  measuring  
the  changes  in  Hemoglobin  concentration  in  Continuous  versus  
Intermittent  iron  therapy  in  children  of  age  6  months  to  5  years  over  a  
period  of  12  weeks  intervention. 
Secondary   objectives: 
To  study  the  changes  in  other  hematological  parameters  pertaining  
to  Iron deficiency anemia  like  Serum  Ferritin  and  Red  cell  indices  like 
Hematocrit,  MCV  and  compliance  and  adverse  effect  profile  in  the  











PHARMACOLOGICAL  PROPERTIES  OF  IRON 
As  the  normal  life  span  of  erythrocytes  is  about  120  days,  there  
needs  to  be  method  for  their  continuous  replacement.  This  process  is  
called  erythropoiesis.  New  cell  production  must  be  matched  to  basal  
needs  and  states  of  increased  demand.  Erythrocytosis  can  be  augmented  
by  more  than  20  fold  in  response  to  anemia  or  hypoxemia.  Similarly,   
leukocytosis  can  increase  dramatically  in  response  to  a  systemic  
infection.  thrombocytosis  can  increase  10–20  times  when  platelet  
consumption  results  in  thrombocytopenia. 
The  control  of  blood  cell  production  is  complex.  Hematopoietic  
stem  cells  are  bone  marrow  derived  cells  that  possess  self-renewal  and  
lineage  commitment,  resulting  in  the  newly  produced  cells  that  are  
destined  to  differentiate  into  the  distinct  blood-cell  lineages.  Major  steps  
in  this  process  occurs  in  the  bone  marrow  cavities  of  flat  bones  like  the  
vertebral  bodies,  skull  and  pelvis  as  well  as  in  the  proximal  regions  of  
long  bones.   
Hematopoiesis  involves  a  complex  interactions  between   
hematopoietic  stem  and  progenitor  cells  in  the  bone  marrow  and  the  
surrounding  complex  macromolecules.   The  process  is  regulated   by  
various  hematopoietic  cytokines.   
Production  of  blood  cells  also  requires  an  adequate  provision   of  
various  trace  elements  like  Iron  ,  Copper  and  cobalt,   and  vitamins  
including  folic  acid,  vitamin  B12,  Vit  B6,  Vit  B2,  and  Vit  C.  
Deficiencies  of  any  of  these  micronutrients  results  in  characteristic  
anemia  or  rarely  a  general  failure  of  hematopoiesis.    
Treatment  of  a  specific  deficiency  state  depends  on  the  accurate  
diagnosis  of  the  cause  of  anemia,  knowledge  about  the  correct  dose  of  
the  preparation  used,  the  use  of  these  agents  in  various  combinations  
and  the  expected  outcome.   
Iron  deficiency  is  the  most  common  nutritional  cause  of  anemia  in  
humans.  Causes  of  iron  deficiency  includes  inadequate  dietary  iron  
intake,  malabsorption,  acute  or  chronic  blood  loss  and  an  increased  
requirement  states  like  childhood  and  pregnancy.  In   severe  deficiency  
states,  it  results  in  a  characteristic  microcytic,  hypochromic  anemia.   
However,  the  impact  of  iron  deficiency  is  not  limited  to  the  
erythrocytes.    Iron  also  is  an  essential  component  of  many  
macromolecules  and  enzymes  like  myoglobin,  heme  containing  enzymes  
such  as  the  cytochromes,  catalase  -  peroxidase  and  the  metallo-
flavoprotein  enzyme  like    xanthine  oxidase  and  the  mitochondrial  
enzymes  like  glycerol phosphate  oxidase.   
Iron  deficiency  can  affect  muscle  metabolism   irrespective  of  the  
state  of  anemia  and  tissue  oxygen  delivery.  This  process  reflects  the  
importance   of  iron  on  mitochondrial  metabolism  in  the  muscle.  Iron  
deficiency  is  well  established  cause  of   behavioral  and  learning  problems  
in  children  and   abnormalities  in  catecholamine  metabolism.    
Recognition  of  the  ubiquitous  role  of  iron  in  the  overall  
metabolism  leads  to  the  concept  of  early  and  accurate  detection  of  iron  
deficiency  and  in  its  prevention. 
Our  understanding  of  iron  metabolism  are  based  on  researches  in  
1937,  with  the  work  of  McCance  and  Widdowson15  on  iron  absorption  
and  excretion  and  Heilmeyer  and  Plotner's  estimation  of  iron  levels  in  
plasma.  Transferrin  was  discovered  in  1947  by  Laurell15 who  described  it  
as  a  plasma  iron  transport  protein.    
In  1948,  Hahn  et  al.,16  first  used  radioactive  isotopes  to  estimate  
iron  absorption.  He  proposed  the  role  of  the  intestinal  mucosa  to  
regulate  the  absorption  of  iron.  Subsequent  Huff  et  al.,  made  isotopic  
studies  of  internal  metabolism  of  iron.  Later  development  of  other  
practical  clinical  measurements  like  serum  iron,  transferrin  saturation,  
plasma  ferritin,  and  erythrocyte  protoporphyrin  permitted  more  accurate  
definition  and  detection  of  the  body's  iron  store  status  and  iron-deficient  
erythropoiesis.   
 
 
Iron  and  the  Environment 
Iron  is  found  in  the  environment  largely  as  insoluble  ferric  oxide  
or  hydroxide  or  as  polymers.  In  this  form,  its  biological  availability  is  
low,  unless  enhanced  by  acid  or  chelating  agents.  Bacteria  and  some  
plants  produce  high-affinity  chelating  agents  that  absorbs  iron  from  the  
surrounding  environment.   
Most  mammals  do  not  have  difficulty  in  acquiring  iron.  This  is  
explained  by  a  sufficient  iron  intake  and  perhaps  also  by  a  greater  
efficiency  in  absorbing  iron.  However  in  Human  beings,  there  seems  to  
appear   an  exception.  Although  total  dietary  consumption  of  elemental  
iron  in  humans  usually  exceeds  requirements,  the  bioavailability  of  the  
iron  in  the  diet  is  low. 
Metabolism  of  Iron. 
The  body  iron  stores  (fig.2)  can  be  divided  into  essential  iron-
containing  compounds  and  excess  iron,  which  is  held  in  storage.  
Quantitatively, hemoglobin   accounts  for  the  major  share  of  essential  





Figure 2: Normal Iron metabolism 
 
Hemoglobin  is  a  protein  with  a  molecular  weight  of  64,500  Da.  It  
contains  four  atoms  of  iron  per  molecule,  amounting  for  1.1  mg  (20  
umol)  of  iron  per  milliliter  of  erythrocytes.  Various  other  forms  of  
essential  iron  are  myoglobin  and  a  variety  of  heme  and  non-heme  iron  
dependent  enzymes.   
Ferritin  is  a  protein,  functions  as  iron  storage  complex.  It  either   
exists  as  individual  molecules  or  as  aggregates.  Apoferritin  has  a  
molecular  weight  of  about  450,000  Da.  It  is  composed  of  24  polypeptide  
subunits  that  form  an  outer  shell.  Within  this  resides  a  storage  cavity  for  
iron  as  polynuclear  hydrous  ferric  oxide  phosphate.  Upto  30%  of  the  
weight  of  ferritin  may  be  iron  that  accounts  for  about  4000  atoms  of  
iron  per  ferritin  molecule.   
Aggregates  of  ferritin  forms  hemosiderin.  It  can  be  seen  under  
light  microscopy.  It  constitute  about  one-third  of  normal  stores.  Its  
fraction  that  increases  as  stores  enlarge.  Reticuloendothelial  system  and  
the  hepatocytes  constitutes  the  two  major  areas  for  storage  of  iron.  But  
muscles  also  offer  some  storage. 
Internal  transport  of  iron  is  caused  by  the  plasma  protein  called  
transferrin.  Transferrin  is  a  76-kDa  glycoprotein.  It  carries  two  binding  
sites  for  ferric  iron.  Iron  is  exchanged  from  transferrin  to  intracellular  
sites  by  a  specific  plasma  membrane  bound  transferrin  receptors.  The  
iron-transferrin  complex  attaches  to  the  cell  surface  receptor,  and  the  
transferrin-receptor  complex  is  internalized  by  means  of  clathrin-coated  
pits  by  receptor-mediated  endocytosis.  A  proton-pumping  ATPase  located  
within  the  endocytosed  complex  lowers  the  pH  of  the  intracellular  
vesicular  compartment  (the  endosomes)  to  about  5.5.  Subsequently  Iron  
dissociates  and  the  receptor  returns  the  apotransferrin  back  to  the  cell  
surface  for  release  into  the  extracellular  environment. 
Cells  regulate  their  expression  of  transferrin  receptors  and  
intracellular  ferritin  in  accordance  to  the  iron  demand.  The  synthesis  of  
transferrin  receptors  in  the  cytoplasmic  membranes  and  apoferritin  is  
regulated  post-transcriptionally  by  two  Iron-Regulatory  Proteins  1  and  
2  (IRP1  and  IRP2).        
These  Iron  regulatory  proteins  are  cytosolic  RNA-binding  proteins  
that  combines  with  iron  regulating  elements  (IREs)  present  in  the  5'  or  
3'  untranslated  segments  of  mRNA  encoding  apoferritin  or  the  transferrin  
receptors,  respectively.  Binding  of  these  IRPs  to  the  5'  IRE  of  apoferritin  
mRNA  represses  translation.  Alternatively,  its  binding  to  the  3'  IRE  of  
mRNA  causes  transcription  of  the  transferrin  receptors  and  increases  
transcript  stability,  thereby  increasing  protein  production.   
When  body  iron  store  is  abundant,  IRP2  undergoes  rapid  
proteolysis  and  IRP1  is  converted  from  a  RNA-binding  protein  into  
aconitase.  This  is  an  enzyme  that  catalyzes  the  interconversion  of  citrate  
and  isocitrate  in  glucose  metabolism.  This  results  in  increased  production  
of  apoferritin  and  thereby  decreased  production  of  transferrin  receptors.   
Conversely,  when  iron  is  in  short  supply,  these  Iron  regulatory  
Proteins  accumulate,  thereby  repressing  translation  of  apoferritin  while  
enhancing  synthesis  of  transferrin  receptors. 
The  total  amount  of  transport  iron  in  the  plasma  amounts  to  a  
total  of  30-40  mg  or  0.46  mg/kg  of  body  weight17.  The  major  internal  
circulation  of  iron  is  between  the  erythroid  mass  and  reticuloendothelial  
cells.  Around  80%  of  the  iron  in  plasma  goes  to  the  red  marrow  of  the  
bones,  to  be  incorporated  into  new  erythrocytes.  These  normally  circulate  
for  120  days  before  being  destroyed   by  the  reticuloendothelial  cells  of  
spleen.  Here  a  portion  of  the  salvaged  iron  and  returned  to  the  plasma  
bound  to  transferrin,  whereas  other  portion  is  packaged  into  the  ferritin  
stores  of  reticuloendothelial  cells.  This  is  returned  to  the  circulation  more  
gradually.   
Isotopic  studies  of  iron  metabolism  indicate  some  degree  of  iron  
loss  in  this  process.  Here  the  defective  cells  or  unused  portions  of  their  
iron  are  transferred  to  the  reticuloendothelial  cell  during  maturation,  
bypassing  the  circulating  blood.  As  in  cases  of  abnormalities  in  
erythrocyte  maturation,  the  predominant  portion  of  iron  assimilated  by  
the  erythroid  marrow  is  rapidly  localized  in  the  reticuloendothelial  cells  
as  defective  red-cell  precursors  are  lysed.  This  process  is  termed  as  
ineffective  erythropoiesis.   
The  rate  of  iron  turnover  in  the  body  may  be  reduced  by  more  
than  half  with  conditions  like  red-cell  aplasia,  with  all  the  iron  directed  
to  the  hepatocytes  for  storage.   
.  
                           Figure 3: Distribution of body Iron stores. 
 
The  most  important  feature   in  the  metabolism  of  iron  (fig.3)  is  
the  degree  to  which  body  stores  are  conserved.  Only  about  10%,  i.e.,  1  
mg/day  of  the  total  is  lost  per  year  by  normal  individuals.   Two-thirds  
of  this  iron  is  excreted  from  the  alimentary  tract  as  extravasated  red  
cells,  iron  content  in  bile,  and  iron  from  the  turn  over  of  intestinal  
mucosal  cells.   
The  remaining   one  third  of  iron  los   is  accounted  for  by  small  
amounts  of  iron  in  desquamated  skin  and  in  the  urine.  Physiological  
losses  of  iron  in  humans  vary  over  a  narrow  range  between  0.5  mg  in  
the  iron-deficient  individual  and  1.5-2  mg  per  day  if  excessive  iron  is  
consumed.   
The  limited  physiological  losses  of  iron  shows  the  primary  
importance  of  intestinal  iron  absorption  in  determining  the  body's  iron  
content18.  Soon  after  acidification  and  start  of  digestion  of  food  in  the  
stomach,  iron  is  presented  to  the  intestinal  mucosa  as  either  inorganic  
iron  or  heme  iron.  An  enzyme  called   ferrireductase,  a  duodenal  
cytochrome  B  located  on  luminal  surface  of  absorptive  cells  of  the  
duodenum  and  upper  small  intestine,  transforms  the  iron  from  the  
trivalent  ferric  form  into  divalent  ferrous  state.   
Ferrous  iron  forms  the  substrate  for  the  Divalent  metal  (ion)  
transporter  1  (DMT1).  The  function  of  DMT1  is  to  transport  the  iron  
molecule  to  basolateral  membrane  of  the  intestinal  epithelial  cells.  Here  
it  is  taken  up  by  another  transporter,  ferroportin   and  again  reoxidized  to  
Fe3+,  primarily  by  Hephaestin.  Hephaestin  is  a  transmembrane  copper-
dependent  ferroxidase  enzyme.  The  resultant  oxidized  iron  gets  bounds  to  
Apo-transferrin. 
  
Figure 4: Mucosal absorption of Iron 
 
Intestinal  mucosal  cell  iron  transport  (fig.4)  and  the  delivery  of  
iron  to  transferrin  from  reticulo-endothelial  stores  are  primarily  
determined  by  the  human  hemochromatosis  protein.  This  is  a  protein  
belonging  to  major  histocompatibility  complex  class  1  molecule  encoded  
by  the  HFE  gene.     
The  gene  for  HFE  is  located  at  the  short  arm  of  chromosome  6  
at  6p21.3.  Its  expression  is  finely  tuned  to  prevent  iron  overload  during  
periods  of  body  iron  excess.  Thus  this  allows  for  increased  absorption  as  
well  as   mobilization  of  iron  stores  during  iron  deficiency.   
A  predominant  negative  modulator  of  iron  absorption  in  the  
duodenum  is  Hepcidin.  It  is  a  25–amino  acid  peptide  chain  synthesized  
by  hepatocytes19.  The  production  of  hepatic  hepcidin  is  greatly  enhanced  
during  inflammation  or  by  iron  overload  states.  A  deficient  hepcidin  
response  to  iron  loading  can  contribute  to  pathological  states  of  iron  
overload.  This  eventually  leads  to  hemochromatosis.   
In  anemia  of  chronic  disease,  hepcidin  production  can  be  
augmented  by  up  to  100-fold.  This  explains  the  characteristic  features  of  
anemia  in  chronic  disease,  comprising  of  poor  GI  uptake  and  enhanced  









Iron  Requirements  and  the  Availability  of  Dietary  Iron 
Iron  requirements  are  mainly  determined  by  obligatory  
physiological  losses  and  the  needs  imposed  by  growth  (Tab.1).  Thus  
periods  of  increased  growth  like   infants  may  require  up  to  1.4  mg  of  
iron  daily. 




Iron  RDA    
(mg/Kg) 
 
Iron  Bioavailability  
(mg/Kg)   
Poor  Diet–Good  Diet 
 
Safety  Factor  
Available/Requirement 
Infant 67 33–66 0.5–1 
Child 22 48–96 2–4 
Adolescent  
(male) 
21 30–60 1.5–3 
Adolescent  
(female) 
20 30–60 1.5–3 
 
Obviously,  infancy  and  preschool  age  represent  periods  of  negative  
iron  balance.   The  balance  between  dietary  intake  and  body  requirements  
is  reflected  by  the  size  of  iron  stores.  This  is  low  or  even  absent  when  
iron  balance  is  adverse  and  high  when  iron  balance  is  favorable.  In  
most  children  after  the  third  month  of  life  and  in  preschool  age  groups,  
stores  of  iron  are  negligible. 
In  developed  countries,  an  average  diet  contains  6  mg  of  iron  per  
1000  calories,  thus  fulfilling  the  an  adequate  daily  iron  intake.  Animal  
meat  such  as  liver  and  heart,  yeast,  egg  yolks,  oysters,  wheat  germ  and  
certain  dried  beans  and  fruits  constitute  iron  rich  foods  with  high  iron  
content  of  more  than  5  mg/100 g. 
Foods  with  low  iron  content  i.e.,  <1  mg/100  g,  are  milk  and  milk  
products  and  most  non-green  vegetables.  The  content  of  iron  in  food  
also  depends  upon  on  the  manner  of  its  preparation,  for  example  iron  
may  be  added  from  cooking  in  iron  pots. 
Even  though  the  iron  content  of  the  food  is  important,  much  
greater  nutritional  significance  lies  on   the  bioavailability  of  iron  in  food.  
Heme  iron,  which  accounts  to  about  6%  of  total  dietary  iron  intake,  is  
far  more  bio-available.  This  is  because  this  for  is  absorbed  independent  
of  the  diet  composition;  Therefore  it  represents  30%  of  dietary  iron  
absorbed.   
But  non-heme  fraction  of  iron  represents  the  largest  amount  of  
dietary  iron  ingested  by  the  people  in  economically  underprivileged.  In  a  
vegetarian  diet,  non-heme  iron  is  absorbed  poorly  because  of  the  
inhibitory  action  of  a  variety  of  dietary  constituents,  particularly  phytates  
and  phosphates ( fig.5).   
 
 Figure 5: Absorption of Non-heme iron 
Conversely  ascorbic  acid  and  meat  increases  the  non-heme  iron  
absorption.  Particularly  ascorbates  forms  complexes  with  ferric  forms  and  
reduces  them  to  ferrous  iron.  Animal  meat  also  facilitates  the  absorption  
of  iron  by  increasing  gastric  acidity.  Either  of  these  substances  can  







Iron  Deficiency 
 Iron  deficiency  is  the  most  common  nutritional  disorder20.  In  
developing  countries,  up  to  20-40%  of  infants  and  preschool  children  
may  be  affected.  Better  iron  balance  can   result  from  the  practice  of  
fortifying  food  stuffs,  by  the  use  of  iron-fortified  formulas  for  infants,  
and  the  prescription  of  iron  supplements  during  pregnancy  and  childhood  
peroids. 
Iron-deficiency  anemia  results  from  inadequate  dietary  intake  of  
iron   to  meet  normal  requirements  (nutritional  iron  deficiency),  blood  
loss,  or  interference  with  iron  absorption.  This  may  be  due  to  genetic  
disease,  as  in  iron-refractory  iron  deficiency  anemia  where   patients  have  
iron  deficiency  that  is  refractory  to  oral  iron  therapy,  but  remain  
partially  responsive  to  parenteral  iron.     
Acquired  conditions  can  also  cause  poor  oral  absorption  and  can  
be   associated  with  impaired  oral  absorption  of  vitamin  B12  or  following  
partial  gastrectomy.  More  severe  iron  deficiency  usually  result  from   
blood  loss,  either  from  the  alimentary   tract,  or  in  through  menstruation  
in  women.  Finally,  treatment  of  patients  with  erythropoietin  can  result  in  
a  functional  iron  deficiency  due  to  erythroid  expansion. 
Iron  deficiency  in  infants  and  young  children  also  lead  to  
behavioral  disturbances  and  can  impair  overall  development.  Some  of  
this  disturbances   may  not  be  fully  reversible.  Iron  deficiency  in  children  
can  lead  to  an  increased  risk  of  lead  intoxication  secondary  to  pica  as  
well  as  an  excess  absorption  of  heavy  metals.  Premature  and  low-birth  
weight  infants  are  particularly  vulnerable  for  developing  iron  deficiency,  
especially  if  they  are  not  breast-fed  or  if  fed  on  noniron-fortified  
formula.  After  the  age  of  2-3  years  the  requirement  for  iron  declines  
gradually.   
The  recognition  of  iron  deficiency  depends  up  on  an  appreciation  
of  the  chain  of  events  that  lead  to  depletion  of  iron  stores.  Initially  a  
negative  balance  results  in  a  decrease  of  iron  stores  and  eventually  a  
parallel  decrease  in  red  cell  iron  and  various  other  iron  related  enzymes.   
In  children  the  depletion  of  iron  stores  can  be  characterised  by  a  
low  plasma  ferritin  (<10  ng/L)  and  the  absence  of  reticuloendothelial  
hemosiderin  in  the  marrow  aspirate.  Iron  deficiency  is  also  identified  by  
a  decreased  saturation  of  transferrin  below  16%  and  a   raised  red-cell  
protoporphyrin  levels.   
Iron  deficiency  anemia  is  characterized  by  a  decrease  in  the  
hemoglobin  concentration  in  blood.  But  the  physiological  variation  in  
hemoglobin  levels  is  so  enormous  that  only  about  half  the  individuals  
with  iron  deficient  erythropoiesis  are  identified  from  their  anemia.   
In  mild  iron  deficiency,  identifying  the  underlying  etiology  is  
more  important  than  any  symptoms  related  to  the  deficiency  state.  
Because  of  the  frequent  incidence  of  iron  deficiency  in  infants,   the  need  
for  elaborate  investigations  of  such  individuals  usually  is  determined  by  
the  severity  of  the  anemia.    
Although  the  presence  of  microcytic  anemia  is  the  most  common  
indicator  of  iron  deficiency,  laboratory  tests  such  as  a  decreased  
reticulocytic  count  and  a  low  serum   ferritin  are  essential  to  distinguish  
iron  deficiency  from  other  causes  of  microcytosis.  Reticulocytic  count  
and  serum  ferritin  are  particularly  useful  when  circulating  eryhtrocytes  
are  not  yet  microcytic  because  of  the  recent  nature  of  blood  loss,  but  a  
low  iron  supply  tend  limits  erythropoiesis.   
Clinically  it  is  more  difficult  to  differentiate  a  true  iron  deficiency  
anemia  from  an  iron-deficient  erythropoiesis  due  to  chronic  inflammation.  
In  the  anemia  of  chronic  disease,  total  body  iron  stores  actually  are  
increased,  but  the  release  of  iron  from  reticuloendothelial  cells  is  
blocked.  Here  the  plasma  iron  concentration  is  decreased,  and  the  supply  
of  iron  to  the  erythroid  marrow  becomes  inadequate.  The  increased  
stores  of  iron  in  this  condition  may  be  demonstrated  directly  by  
examination  of  an  aspirate  of  marrow  or  may  be  seen  in  laboratory  
determination  of  an  elevated  plasma  concentration  of  ferritin. 
 
TREATMENT  OF  IRON  DEFICIENCY 
General  Therapeutic  Principles 
The  clinical  response  of  iron  deficiency  anemia  to  therapy  is  
influenced  by  several  factors,  including  the  severity  of  anemia,  the  
ability  of  the  patient  to  tolerate  and  absorb  medicinal  iron,  and  
associated  complicating  illnesses.   
Therapeutic  effectiveness  is  best  measured  by  the  post  
supplemental   increase  in  the  rate  of  production  of  erythrocytes.  The  
magnitude  of  the  marrow  response  to  hematinic  therapy  is  directly  
proportional  to  the  severity  of  the  anemia   and  the  amount  of  iron  
delivered  to  erythropoietic  precursors. 
The  patient's  ability  to  tolerate  and  absorb  the  orally  administered  
iron  is  a  key  factor  in  determining  the  rate  of  response  to  therapy.  The  
small  intestine  regulates  absorption.  As  the  doses  of  orally  administered  
iron  increases,  entry  of  iron  into  the  bloodstream  gets  limited.  This  
provides  a  natural  ceiling  on  dose  of  iron  can  be  supplied  by  oral  
therapy.   
In  the  patient  with  a  moderately  to  severe  iron  deficiency  anemia,  
tolerable  doses  of  oral  iron  will  deliver,  at  most,  20  –  30  mg  of  iron  
per  day  to  the  erythroid  marrow.  This  is  an  amount  sufficient  for  
erythropoiesis  to  proceed  at  the  rates  of  two  to  three  times  normal. 
Co-existing  medical  illness  also  can  interfere  with  the  response  of  
an  iron-deficiency  anemia  to  iron  therapy.  By  decreasing  the  number  of  
erythropoietic  precursors,  intrinsic  disease  of  the  marrow  can  blunt  the  
response.   
Any  chronic  inflammatory  illnesses  suppress  the  rate  of  red  cell  
production,  either  by  reducing  iron  absorption  and  reticuloendothelial  
release  or  by  direct  inhibition  of  erythropoietin  and  erythroid  precursors.  
Continued  blood  loss  can  compromise  the  response  to  iron  therapy  as  
measured  by  recovery  of  the  hemoglobin  or  packed  cell  volume. 
Clinically,  the  effectiveness  of  iron  therapy  is  best  evaluated  by  
assessing  the  an  increasing  reticulocyte  count  and  the  rise  in  the  
hemoglobin  or  the  packed  cell  volume.  An  increase  in  the  reticulocyte  
count  is  observed  in  3-6  days  after  beginning  therapy.  A  measurable  
increase  in  the  hemoglobin  level  takes  even  longer  peroid  following  
initiation  of  iron  therapy.   
A  decision  about  the  effectiveness  of  iron  should  not  be  made  
within  3-4  weeks  after  the  start  of  treatment.  An  increase  of  1-2  g/dl  in  
the  concentration  of  hemoglobin  by  that  time  should  be  considered  an  
adequate  response,  assuming  that  no  other  change  in  the  patient's  clinical  
status  can  account  for  the  improvement  and  that  the  patient  has  not  been  
transfused. 
If  the  response  to  oral  iron  is  inadequate,  it  is  prudent  to  
reconsider  the  diagnosis.  A  thorough  laboratory  workup  should  be  
conducted  and  poor  compliance  by  the  patient  or  the  presence  of  a  
concurrent  inflammatory  disease  must  be  looked.  Concurrently  any  source  
of  continued  bleeding  obviously  should  be  sought.  If  these  are  found  
negative  then  an  evaluation  of  the  patient's  ability  to  absorb  oral  iron  
should  be  considered.   
It  is  not  justified  to  merely  continue  with  oral  iron  therapy  
beyond  3-4  weeks  if  a   favorable  response  has  not  occurred. 
Once  a  positive  response  to  oral  iron  is  demonstrated,  therapy  
should  be  continued  until  the  hemoglobin  value  gets  normalized.  
Treatment  may  be  continued  if  it  is  desirable  to  replenish  iron  stores.  
This  may  require  a  considerable  period  of  time  because  the  rate  of  
absorption  of  iron  by  the  intestine  will  fall  remarkably  as  iron  stores  are  
restored.   
The  use  of  prophylactic  oral  iron  should  be  reserved  for  patients  
at  high  risk  of  developing  iron  deficiency,  including  pregnant  women,  
women  with  excessive  menstrual  blood  loss  and  infants.  Iron  
supplements  also  may  be  indicated  in  rapidly  growing  infants  who  are  
consuming  substandard  diets  and  for  adults  with  a  recognized  cause  of  
chronic  blood  loss. 
  
Therapy  with  Oral  Iron 
Oral  ferrous  sulfate  preparation  is  the  treatment  of  choice  for  iron  
deficiency  anemia.  Ferrous  salts  are  absorbed  about  three  times  better  
than  ferric  salts.  This  discrepancy  becomes  even  greater  at  high  oral  
dosages.  Variations  in  the  particular  ferrous  salt  do  not  greatly  influence  
bioavailability  following  oral  administration.   
The  oral  salts  such  as  sulphate,  fumarate,  succinate,  gluconate,  
aspartate,  other  ferrous  salts,  and  polysaccharide  ferrihydrite  complex  are  
absorbed  to  approximately  the  same  extent.  The  effective  dose  of  all  of  
these  preparations  is  based  on  their  elemental  iron  content. 
Other  iron  compounds  have  their  role  in  fortification  of  foods  
stuffs.  Reduced  iron  such  as  metallic  iron  and  elemental  iron  are  as  
effective  as  ferrous  sulfate,  if  the  preaparations  used  have  small  particle  
size.  Large  size  of  the  particle  such  as  ferrum  reductum  and  salts  of  
iron  phosphate  have  a  much  lower  bioavailability.  When  these  are  
employed  for  the  fortification  of  foods  have  been  undoubtedly  
responsible  for  some  of  the  confusion  concerning  effectiveness  of  food  
fortification.   
Salts  such  as  Ferric  edetate  has  been  shown  to  have  good  
bioavailability.  They  additionally  have  advantages  for  maintenance  of  the  
normal  appearance  and  taste  of  food  upon  food  fortification. 
The  amount  of  elemental  iron,  rather  than  the  mass  of  the  total  
salt  in  iron  tablets  is  important.  It  is  also  important  that  the  coating  of  
the  tablet  should  dissolve  rapidly  in  the  stomach.  Interestingly,  because  
iron  usually  is  absorbed  in  the  upper  small  intestine,  certain  sustained  
release  formulations  have  been  reported  to  be  as  effective  as  uncoated  
tablets.  They  have  been  said  to  be  even  more  effective  than  ferrous  
sulfate  when  taken  with  meals.   
 Numerous  substances  are  designed  to  enhance  the  absorption  of  
iron.   They  include  surface-acting  agents,  carbohydrates,  inorganic  salts,  
amino  acids  and  vitamins  like  ascorbic  acid.  When  present  in  an  amount  
of  200mg,  vitamin  C  enhances  the  absorption  of  orally  administered  iron  
by  at  least  30%.  However  the  enhanced  uptake  is  associated  with  a  
significant  increase  in  the  incidence  of  adverse  effects. 
  Therefore,  the  addition  of  ascorbic  acid  seems  to  offer  little  
advantage  over  increasing  the  dose  of  iron  administered.  It  is  not  
advisable  to  use  preparations  that  contain  other  compounds  with  intrinsic  
therapeutic  actions  of  their  own  like  Cyanocobalamine,  Folate,  or  Cobalt  
because  the  patient's  response  to  the  combination  are  difficult  to  
interpreted. 
The  average  therapeutic  dose  of  iron  for  the  treatment  of  iron-
deficiency  anemia  is  about  3-6  mg/kg  per  day.  Children  weighing 15-30  
kg  can  take  half  the  average  adult  dose;  small  children  and  infants  can  
tolerate  relatively  large  doses  of  iron  i.e.,  up  to  5  mg/kg.   
The  dose  employed  should  be  a  balance  between  the  desired  
therapeutic  action  and  the  adverse  effects.  Prophylaxis  as  well  as  mild  
nutritional  iron  deficiency  may  be  managed  with  modest  doses  of  oral  
iron.  While  treatment  is  the  object,  a  dose  of  2-3  mg/kg  per  day  is  
employed. 
The  expected  outcome  for  different  dosage  regimens  of  oral  iron  
varies.  These  effects  are  influenced  by  the  severity  of  the  iron  deficiency  
anemia  and  by  other  factors  such  as  the  time  of  intake  of  iron  relative  
to  meals.  Bioavailability  of  iron  taken  with  food  is  probably  one-half  or  
one-third  of  that  observed  in  the  fasting  subject.     
Antacids  greatly  reduce  iron  absorption  if  both  are  given  
concurrently.  It  is  always  preferable  to  administer  iron  in  the  empty  
stomach.  In  such  conditions,  even  the  dose  may  be  reduced  to  lessen  the  
gastrointestinal  adverse  effects.    
Sustained  high  rates  of  erythropoiesis  needs  an  uninterrupted  
supply  of  iron.  The  oral  doses  of  iron  should  be  spaced  equally  to  
maintain  a  adequate  concentration  of  iron  in  plasma (Tab.2). 
 
 
TOTAL  DOSE  
OF  IRON 
 
ESTIMATED  ABSORPTION 
 
INCREASE  IN  
Blood  Hb 
(mg/day) % mg (g/L/day) 
35 40 14 0.7 
105 24 25 1.4 
195 18 35 1.9 
390 12 45 2.2 
Table 2: Response to iron therapy. 
The  duration  of  treatment  is  influenced  by  the  rate  of  recovery  of  
hemoglobin  and  the  target  iron  storage  level.  The  former  depends  on  the  
severity  of  the  initial  anemia.  With  a  daily  rate  of  replenishment  of  0.2  
g/dl  of  hemoglobin,  the  red-cell  mass  usually  is  normalized  within  1-2  
months.  Thus  an  individual  with  a  hemoglobin  of  5  g/dl  may  achieve  a  
normal  complement  of  15  g/dl  in  50  days,  while  an  individual  with  a  
hemoglobin  of  10  g/dl  may  take  only  half  that  time.   
The  creation  of  stores  of  iron  requires  several  months  of  oral  iron  
therapy.  The  rate  of  absorption  decreases  dramatically  soon  after  
recovery  from  anemia  and  by  3  -  4  months  of  treatment,  stores  may  
increase  at  a  rate  of  not  much  more  than  100  mg/month.   
The  plan  of  the  strategy  of  continued  therapy  depends  on  the  
estimated  future  iron  reserve.  Patients  with  a  diet  inadequate  in  iron  may  
require  continued  therapy  with  low  doses  of  iron.  If  the  bleeding  has  
arrested,  then   further  therapy  is  not  required  after  the  hemoglobin  has  
returned  to  normal.  With  continued  bleeding,  long  term,  high  dose  iron  
therapy  is  indicated. 
Untoward  Effects  of  Oral  Preparations  of  Iron 
Intolerance  to  oral  preparations  of  iron  manly  related  to  the  
amount  of  soluble  iron  in  the  upper  GI  tract.  Psychological  factors  also  
play  a  role.  Side  effects  include  epigastric  pain,  nausea,  upper  gastric  
discomfort,  heartburn  and  diarrhea  or  constipation.   
It  will  be  more  acceptable  to  initiate  therapy  at  a  small  dosage,  to  
demonstrate  freedom  from  adverse  effects  at  that  level  and  then  
gradually  to  raise  the  dosage  to  the  desired  level.  With  a  dose  of  200  
mg  of  iron  per  day  divided  into  three  doses,  symptoms  occur  in  25%  of  
treated  individuals  vs  13%  among  those  receiving  placebo.  This  increases  
to  about  40%  when  the  dosage  of  iron  is  doubled.   
Nausea  and  upper  abdominal  pain  are  more  common  at  high  
dosage.  Constipation  and  diarrhea,  both  related  to  iron-induced  changes  
in  the  intestinal  bacterial  flora,  are  not  more  seen  at  higher  dosage.   
  If  a  syrup  formulation  is  used,  one  can  place  the  iron  solution  
on  the  back  of  the  tongue  with  a  dropper  to  prevent  transient  teeth  
staining. 
The  normal  individual  have  the  capacity  to  control  absorption  of  
iron  despite  high  intake.   Only  individuals  with  underlying  disorders  that  
augment  the  absorption  of  iron  have  the  hazard  of  developing  iron  



































REVIEW  OF  LITERATURE 
The   initial  concept  regarding  intermittent  iron  supplementation  
comes   from  studies  on  iron-deficient  rats.  In  the  iron  deficient  rats,  the  
true  absorptive  and  iron  retention  capacities  for  iron  declined  rapidly  
when  iron  was  given  on  daily  basis  rather  than  on  intermittent  
administration.  These  studies  gave  rise  to  many  human  studies  that  
generally  showed  adequate  efficacy  compared  with  daily  iron  
supplementation  in  terms  of  Hemoglobin  levels  and  safe  increments  of  
iron  reserves. 
Beaton  and  McCabe21,  in  an  analysis  of  experiences  with  
intermittent  and  daily  iron,  initially  suggested  that  daily  iron  
supplementation  was  superior  to  intermittent  supplementation  in  
pregnancy  on  the  basis  of  Hemoglobin  responses.  Beaton  later  recognized  
that  the  original  estimation  of  superiority  of  daily  supplementation,  if  
adjusted  by  the  pregnancy  stage  at  which  the  iron  supplementation  
intervention  started,  essentially  disappeared.   
In  1958,  Bothwell  et  al., 22  published  studies  from  which  they  
concluded  that  both  the  size  of  iron  stores  and  the  rate  of  erythropoiesis  
influenced  iron  absorption  in  humans. 
The  theory  behind  intermittent  oral  iron  supplementation  was  based  
initially  on  the  concept  of  a  “mucosal  block”  of  iron  absorption23 .  Early  
studies  have  shown  that  a  single  bolus  of  oral  iron  could  inhibit  the  
absorption  of  a  test  dose  of  radio  iron  given  only  a  few  hours  later24. 
The  rapid  development  of  this  refractory  state,  referred  to  as  the  
“mucosal  block,”  supported  the  notion  of  local  regulation  of  iron  
absorption  by  the  enterocyte  and  more  particularly  by  its  ferritin  
content26.  Based  on  this  theory  argues  that  mucosal  enterocytes  down-
regulate  iron  absorption  in  response  to  daily  exposure  to  a  high  intake  
of  iron.  There  is  an  increase  in  mucosal  ferritin  synthesis,  an  increase  in  
the  proportion  of  enterocyte  iron  that  is  stored  in  the  cell,  and  a  
decrease  in  transfer  of  iron  to  transferrin  in  the  vascular  pool.   
The  current  view  is  that  hepcidin  inhibits  the  release  of  iron  from  
absorptive  enterocytes  and  iron-recycling  macrophages  into  the  circulation  
by  binding  to  and  promoting  the  internalization  and  subsequent  
degradation  of  Ferroportin26.  Iron  is  then  stored  in  ferritin  and  lost  when  
mucosal  cells  exfoliate. 
Based  on  these  observations,  Fernando  E.  Viteri  et  al.,27   showed  
the  True  absorption  and  retention  of  supplemental  iron  is  more  efficient  
when  iron  is  administered  intermittently  rather  than  daily  to  iron-normal  
and  iron  deficient  rats.  In  the  study  he  observed  a  very  rapid  decrease  
in  true  iron  absorption  that  takes  place  when  a  daily  iron  supplement  
equivalent  to  10  times  the  normal  intake  is  administered  preceding  two  
meals  in  rats  trained  to  meal-feed  twice  daily.   
This  marked  and  rapid  decrease  is  observed  in  both  iron  normal  
and  iron-deficient  rats,  revealing  the  blocking  effect  of  previous  high  
iron  intake  and  the  effect  of  iron  repletion  on  iron  absorption  thereby   
questioning  the  common  daily  iron  supplementation  practices  in  humans. 
Outcomes  of  iron  studies  on  rats  lead  to  the  suggestion  that  iron  
supplementation  need  not  be  given  on  daily  basis,  but  can  rather  be  
given  on  weekly  or  twice  weekly  manner.  In  daily  dose,  the  intestinal  
mucosal  cells  get  saturated  quickly  and  iron  absorption  decreases.  As  the  
turnover  rate  of  these  cells  is  3  to  5  days,  a  biweekly  dose  may  be  as  
efficacious  and  more  cost-effective.   
Compliance  might  also  improve  because  fewer  doses  of  iron  
would  be  needed.  This  hypothesis  has  been  supported  by  studies  
comparing  the  effectiveness  of  hemoglobin  or  hematocrit  response,  which  
was  found  to  be  similar  regardless  of  whether  supplementation  was  
daily,  weekly,  or  twice  weekly28. 
Schultink  W  et  al.,29  studied  the  effect  of  daily  vs  twice  weekly  
iron  supplementation  on  iron  status  in  preschool  children  with  low  iron  
status  in  a  randomized  double-masked  field  trial.  A  total  of  87  Subjects  
were  selected  on  the  basis  of  their  hemoglobin  concentration  being  <  11  
g/L  in  finger-prick  blood,  and  were  divided  into  two  groups.   
During  the  8  weeks  peroid  one  group  received  a  daily  supplement  
of  30  mg  elemental  iron,  while  the  other  group  received  30  mg  iron  
twice  per  week.  A  complete  data  set  was  obtained  from  32  children  in  
the  group  supplemented  daily  and  from  33  children  in  the  group  
supplemented  twice  weekly.  Hemoglobin  and  serum  ferritin   increased  
significantly  in  both  groups  (P  <  0.001).  The  difference  in  treatment  
effect  between  groups  was  not  significant  after  correction  for  the  initial  
hemoglobin  concentration.   
It  is  concluded  that  in  preschool  children  with  low  iron  status,  
twice  weekly  iron  supplementation  has  an  effect  on  iron  status  similar  to  
that  of  daily  supplementation.  The  major  limitation  of  the  study  was  a  
small  sample  size  and  a  shorter  period  of  intervention  both  compromises  
the  power  of  the  study. 
James  D  Cook  and  Manju  B  Reddy30  in  their  research  titled  
Efficacy  of  weekly  compared  with  daily  iron  supplementation,  studied  the  
iron  absorption  from  50  mg  radiolabeled  ferrous  sulphate  in  23  healthy  
female  volunteer  subjects  divided  into  two  groups.  The  first  group  
received  a  labeled  ferrous  sulphate  supplement  was  given  with  water  and  
in  the  second  group  it  was  given  with  a  rice-based  meal.   
  In  both  groups,  absorption  was  measured  in  a  randomized  fashion  
twice  in  each  subject,  once  with  daily  and  once  with  weekly  
supplementation.  Those  tested  for  daily  supplementation  were  given  an  
iron  supplement  daily  for  6  days  before  testing  whereas  those  tested  for  
weekly  supplementation  were  given  no  iron  for  6  days  before  testing.   
When  the  labeled  iron  supplement  was  given  with  water  only,  
absorption  averaged  8.5%  with  daily  and  9.8%  with  weekly  
administration  compared  with  2.3%  and  2.6%,  respectively,  when  given  
with  food.  The  13%  lower  absorption  observed  with  daily  administration  
in  both  groups  was  not  statistically  significant  (P  >  0.20).  These  results  
indicate  that  there  is  no  significant  absorptive  advantage  in  giving  iron  
less  often  than  once  daily. 
Similarly,  Hallberg31  reiterated  that  there  is  no  evidence  that  
weekly  supplementation  better  prevents  iron  deficiency  because  the  
fundamental  argument  in  its  favor,  that  daily  supplementation  causes  a  
mucosal  block,  is  not  valid.   
  The  controversy  appears  to  have  been  put  to  rest  by  a  meta-
analysis   by  Beaton  and  McCabe21  analyzed  the  outcome  of  intermittent  
iron  therapy  in  the  prevention  of  iron  deficiency  anemia  in  developing  
countries.  This  was  done  based  on  the  systematic  analysis  of  results  of  
22  completed  studies  on  iron  supplementation.    
The  outcome  in  the  individual  projects  are  catogorized  into  three  
groups:  pregnant  women,  school-age  children  &  adolescents  and  
preschool  children.  The  result  concluded  that  that  both  daily  and  weekly  
iron  therapy  are  equally  efficacious  in  the  prevention  of  anemia.  But  
daily  administration  is  found  to  be  more  effective  than  biweekly  iron   
except  in  situations  where  supervision  is  feasible  with  weekly  regimens  
and  not  with  daily  supplementation.   
Binay  Kumar  Shah  et  al.,32  compared  the  effectiveness  of  weekly  
vs  daily  iron  and  folic  acid  supplementation  for  control  of  anemia  in  
adolescent  Nepalese  girls  and  concluded  that  weekly  supervised  therapy  
is  a  good  alternative  to  daily  iron  and  folic  acid  administration.  Weekly  
therapy  appears  to  be  equally  effective  yet  causes  fewer  adverse  effects,  
improves  compliance,  and  reduces  the  cost  of  supplementation. 
Based  on  these  studies  WHO  in  its  position  statement  on  Weekly  
Iron  and  Folic  Acid  Supplementation  (WIFS)  for  Preventing  Anemia33 ,  
recommends  a  weekly  supplementation  iron  in  the  form  of  ferrous  






Study  justification   
Concluding  from  the  above  reviews,  comparable  efficacy  of  
improvement  in  hemoglobin  with  both  intermittent  and  daily  iron  therapy  
is  seen  in  most  studies.  However  most  of  the  studies  were  done  in  
adolescent  girls  and  women  of  child  bearing  age.   
Data  on  the  efficacy  of  intermittent  regimen  supplementation  of  
iron  in  preschool  children   is  scarce.  Therapeutic  daily  iron  given  for  the  
treatment  of  iron  deficiency  anemia  causes  many  undesirable  adverse  
effects,  leading  to  poor  drug  compliance.   
Presently,  prophylactic  intermittent  iron  supplementation  has  been  
accepted  except  in  antenatal  programs,  for  which  debate  is  ongoing.  The  
biweekly  dosage  schedule  takes  advantage  of  the  turnover  time  for  
intestinal  mucosal  cells  in  humans,  which  is   3   to   5  days,  favoring  the  
regulation  of  iron  absorption  and  avoiding  the  daily  exposure  of  an  iron-










STUDY  DESIGN:  Interventional  study   
RANDOMIZATION  METHOD  :  Lottery  randomization  technique. 
STUDY  PLACE  :   
Outpatient  department  and  inpatient  wards  of  Institute  of  Social  
Pediatrics,  Government  Stanley  Medical  College,  Chennai  600  001. 
STUDY  PERIOD  :   
September  2014  to  August  2015 
ETHICAL  CLEARANCE  :   
Approved  by  the  institutional  ethics  committee. 
STUDY  SUBJECTS  :   
Children  of  age  6  months  to  5  years  with  Iron  deficiency  anemia  
attending  the  study  center. 
SOURCE  OF  FUNDING  :    None. 
CONFLICT  OF  INTEREST  :   None. 
 
 
CASE  DEFINITION:    
Anemia34  in  the  age  group  of  6  months  to  5  years  is  defined  as  
a  reduction  of  the  hemoglobin  concentration  (Hemoglobin  <  11g/dL)  or  
Red blood  cell  volume  (Mean  Corpuscular  Volume  <  70  uM3).   
Iron  deficiency  anemia  is  characterized  by  the  presence   microcytic  
hypochromic  anemia,  low  reticulocytic  count  and  a  low  serum  ferritin  
level  (  <  12  ng/ml  ).   
INCLUSION  CRITERIA: 
Children  of  age  group  between  6  months  to  5  years,  attending  the  
pediatric  health  services  with  clinical  features  of  anemia   and  those  show  
laboratory  evidence of anemia  will  be  enrolled  for  the  study. 
EXCLUSION  CRITERIA: 
1. Those  children  who  are  already  on  iron  supplementation. 
2. Those  children  who  had  blood  transfusion  during  the  past  3  
months. 
3. Children  with  severe  anemia  as  defined  as  Hemoglobin  of  less  
than  7.0  gm/dL  or  those  with  complications  of  anemia  were  
excluded. 
4. Acute  illness  during  the  study  or  within  the  past  one  month 
5. Those  with  chronic  illness  and  ongoing  blood  loss. 
Those  with  intolerable  adverse  effects  due  to  iron  therapy  and  failure  
to  show  adequate  response  will  be  excluded  from  the  study  at  any  
point  of  time  for  further  evaluation  and  treatment.   
Children  with  anemia  due  to  causes  and  those  not  showing  adequate  
erythropoiesis  on  follow  up  will  be  excluded  from  the  study  and  will  be  
evaluated  separately.   
Sample  size  calculation: 
    To  detect  a  mean  difference  of  1  g/dl  hemoglobin  between  the  
intervention  and  control  groups  with  80%  power  and  5%  significance,  
assuming  a  standard  deviation  of  2.0  g/dl;  63  subjects/group  are  required.  
Assuming  a  loss  to  follow-up  of  20%,  the  final  sample  size  is  70  









1. Informed  written  consent  is  obtained  from  the  parents  to  undergo  
the  study. 
2. Children  are  clinically  screened  for  anemia  by  history  and  physical  
Examination. 
3. Blood  samples  are  collected  under  sterile  aseptic  precautions. 
4. Blood  samples  for  hemoglobin  estimation,  peripheral  smear  study,  
hematocrit,  red  cell  indices  were  collected  in  2ml  K3  EDTA  
vacutainer  tubes  (  Yucca  TubeTM,  Yucca  diagnostics,  India  ). 
5. Serum  samples  for  serum  ferritin  estimation  is  collected  in  2  ml  
vacutainer  with  clot  activator(  Hemo  TubeTM   ,  MB  Lab  
Consumables,  India  )  and  estimation  done  by  ELISA  method. 
6. Automated  cell  counter  (Horiba  ABX  Cell  counter,  France  )  is  
used  for  estimation  of  Hemoglobin,  Hematocrit  and  red  cell  
indices.  Gross  variations  in  results  were  manually  tested  by  
Cyanmet  Hemoglobin  method.   
7. Peripheral  Smear  Study  :  Done  using  Leishman  stain  and  studied  
by  pathologist  for  morphological  changes  of  iron  deficiency  
anemia.  Children  with  typical  features  of  iron  deficiency  anemia  
like  microcytic  and  hypochromic  erythrocytes  were  enrolled  for  the  
study.  Subjects  with  other  causes  of  anemia  like  hereditary  
spherocytosis,  megaloblastic  anemia,  hemolytic  diseases  like  sickle  
cell  disease  and  thalassemia  will  be  excluded  from  the  study  for  
further  evaluation.   
8. Reticlocyte  Count  :  Done  by  Pathologist  using  Methylene  Blue  
stain  (  NICE  Reticulocyte  Fluid  TM  ).  Blood  samples  collected  in  
EDTA  tubes  were  used  for  the  study.  Equal  volume  of  
reticulocyte  count  fluid  is  added  to  the  anti-coagulated  blood  
sample  and  incubated  for  30  minutes.  Then  a  smear  is  made  is  
on  a  glass  slide  and  the  fraction  of  reticulocytes  per  100  RBC  
estimated  to  give  the  Reticulocytic  count.  Reference  values  are  
provided  in Tab.3.Reference  values 
Table 3: Reference value of hematological parameters. 
PARAMETERS MEAN LOWER  LIMT 
Hemoglobin  (  g/dl  ) 12.5 11.0 
Hematocrit  (  %  ) 
0.5  –  1.9  years 







MCV  (uM3  ) 
0.5  –  1.9  years 







Reticulocyte  count 0.5  to  1.5  %  of  erythrocytes 
Serum  Ferritin 10  to  60  ng  /  dl 
 
9. Iron  Preparation: The  drug  used  for  intervention  in  both  group  is  
Ferrous  sulphate  and  Folic  acid  syrup  with  each  1  ml  containing  
Ferrous  Sulphate  IP  100  mg  (equivalent  to  elemental  iron  20  mg)  
and  Folic  acid  IP  100mcg  (Biogenetics  Drugs  Pvt.  Ltd.  India,  
procured  by  hospital  pharmacy  through  Tamil  Nadu  Government  
supplies).   
10. Ferrous  sulphate  is  chosen  as  the  preparation  of  iron  since  it  
cheaper  than  most  other  iron  formulation  and  since  it  is  the  
preparation  used  in  National  programmes,  the  result  of  the  study  
can  be  directly  extrapolated  for  further  community  interventions. 
11. Children  were  weighed  using  electronic  weighing  scale  at  the  start  
of  the  study  and  were  prescribed  3  mg/kg  of  elemental  iron  –  
twice  a  week  i.e.,  on  Monday  and  Thursday  for  intermittent  
treatment  group  and  everyday  in  Daily  regimen  group.  Mothers  are  
advised  to  give  the  drug  one  hour  before  or  after  the  food  and  
tea  in  order  to  improve  the  bioavailability  of  iron.   
12. Deworming: All  the  children  were  dewormed  with  oral  
Albendazole,  based  on  WHO  recommendations34  -  200  mg  
chewable  tablets  for  children  1-2  years  and  400  mg  chewable  
tablets  for  children  above  2  years.  Chewable  tablets  are  preferred  
to  avoid  the  choking  hazard  due  to  the  large  size  of  the  
Albendazole  tablet  
13. The  children  with  IDA  are  randomly  allocated  into  Group  A   
(  Controls  )  and  Group  B  (  Study  group  )  by  random  lottery  
method. 
14. Children  in  Control  group  will  receive  3  mg  /  kg  elemental  iron  
daily  and  those  in  Test  group  will  receive  the  same  twice  weekly  
(Monday  and  Thursday)  for  12  weeks. 
15. Drug  will  be  sourced  from  the  Hospital  Pharmacy.  This  includes  
Ferrous  Sulphate  syrup  containing  100mg  elemental  iron  per  5ml  
and  albendazole  400mg  chewable  tablet. 
16. Followed  up  at  3-5 days with reticulocyte count, at 4 weeks with 
hemoglobin and drug compliance and at 12 weeks for Hemoglobin  and 
other red cell indices like PCV  and MCV along with drug compliance  
and  adverse  effect  assessment  (  using  the  checklist  ). 
17. Management  of  adverse  events: Mothers  were  informed  about  the  
possible  adverse  effects  of  ferrous  sulphate  and  folic  acid  syrup  
and  albendazole.  Mothers  were  cautioned  about  accidental  overdose  
with  Iron  syrup  and  the  consequent  serious  toxicities.  All  mothers  
are  instructed  to  bring  the  child  to  medical  attention  with  any  
overdose  of  the  prescribed  medicines  or  untoward  effects  following  
the  drug  administration.  Mothers  are  informed  about  the  harmless  
nature  of  occasional  black  colored  stools  that  may  be  seen  in  
children  on  iron  supplementation.  The  risk  of  teeth  staining  was  
explained.  Any  emergency  medical  issue  will  be  attended  in  the  
24  hrs  pediatric  casualty.  
Statistical  Analysis:  
Intention-to-treat  analysis  will  be  followed  to  eliminate  potential  
bias  of  excluding  the  subjects  who  do  not  comply  or  not  available  
for  follow-up.  Data  were  in  Microsoft  excel  sheets.   Statistical  
analysis  were  done  using  IBM  SPSS  version  20.0  software  package  
using  computer.  Methods  included  mean,  standard  deviation,  Paired  t  














OBSERVATIONS  AND  RESULTS 
























140 Enrolled for the study 
Randomization 
Intermittent supplementation 






n = 70 
 
68 completed the study 
 
2 lost on follow up 5 lost on follow up 
 
65 completed the study 
Out  of  the  140  children  enrolled  for  the  study  (tab.4 & chart 4),  2  
from  the  intermittent  supplementation  group  and  5  from  the  daily  
supplementation  group  were  lost  on  follow  ups.  Final  reevaluation  was  
done  on  68  subjects  in  intermittent  supplementation  group  and  65  
subjects  in  daily  supplementation  group.   
























































Final  follow  up  evaluation  included  clinical  examination  and  lab  
tests  for  estimation  of  hemoglobin,  hematocrit,  mean  corpuscular  volume  
and  serum  ferritin  assay.  The  age-wise  distribution  of  the  sample  
population  is  shown  in  table  1.   The  mean  hemoglobin  concentration  and  
the  number  of  subjects  in  each  group  appear  to  be  similar  in  both  the  
groups  before  intervention.  (Tab. 5). 














Daily  Regimen 
 
 




































Table  6:  Comparison  of  hematopoietic  response  of  both  study  










p  value 
 
 







1.24  +/-  0.35 
2.16  +/-  0.25 




1.16  +/-  0.34 
2.57+/-  0.38 






p  <  0.001 
 
 
The  initial  mean  reticulocyte  count  was  1.24  %  of  erythrocytes  
with  a  standard  deviation  of  0.35  %.   The initial reticulocyte count of the 
daily iron therapy group was 1.16 +/- 0.34. The  reticulocyte after 3-5 days  in 
the intermittent and daily iron therapy groups were 2.16 +/- 0.25 and 2.57 +/- 
0.38 respectively showing a significant reticulocytosis in both groups ( p < 



















Initial  Hb 
 
 
Hb  at  4  weeks 
 
 




































































The  age-wise  improvement  in  hemoglobin  concentration  of  children  
on  intermittent  iron  therapy  is  shown  in  Table  7  and  chart  2.  This  
showed  an uniform   rise  in  hemoglobin  in  all  age  groups  studied 
Chart  2:  Follow  up  of  Hemoglobin  in  Intermittent  treatment  group. 
 
 
Initial  mean  hemoglobin  in  the  intermittent  iron  supplementation  
group  was  8.58  g/dl  with  a  standard  deviation  of  1.07  g/dl.  The  mean  
initial  Hematocrit  was  26.06  %  with  a  standard  deviation  of  3.40.  The  
mean  initial  mean  corpuscular  volume  was  71.03  µM3  with  a  standard  
deviation  of  1.05  µM3  .   Initial  serum ferritin  was  10.18  ng/L  with  a  
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 In  the  final  assessment  of  intermittent  iron  supplementation  group  
after  12  weeks,  hemoglobin  increased  by  a  mean  of  3.22  +/-  0.75  g/dL.  
Mean  corpuscular  volume  increased  by  6.75  +/-  1.69  uM3,  PCV  
increased  by  9.14  +/-  2.71  %  and  serum  ferritin  increased  by  14.21  +/-  
5.52  ng/ml.  The  final  increase  was  statistically  significant  with  regards  to  
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The  age-wise  improvement  in  hemoglobin  concentration  of  children  
on  daily  iron  therapy  is  shown  in  Table  7  and  chart  2.  This  showed  an 
uniform   rise  in  hemoglobin  in  all  age  groups  studied. 
 
Chart  3:  Follow  up  of  Hemoglobin  in  Daily  treatment  group 
 
 
In  the  daily  iron  supplementation  group,  the  initial  mean  
Hemoglobin  was  8.47  g/dl  with  a  standard  deviation  of  1.01  g/dl (tab 9 ).  
The  mean  initial  Hematocrit  was  25.66  %  with  a  standard  deviation  of  
2.89.  The  mean  initial  mean  corpuscular  volume  was  70.92  µM3  with  a  
standard  deviation  of  1.46  µM3 . 
  The  initial  mean  reticulocyte  count  was  1.16  %  of  erythrocytes  
with  a  standard  deviation  of  0.34  %.  Initial  mean  serum  ferritin  was  









6 MONTHS TO 
1 YEAR
1 YEAR TO 2 
YEARS
2 YEARS TO 3 
YEARS
3 YEARS TO 4 
YEARS



















Age distribution VS change in Hb
HB 1 HB 2 HB 3
  



















           In  the  final  assessment  of  daily  iron  supplementation  group  after  
12  weeks,  hemoglobin  increased  by  a  mean  of  3.52  +/-  0.78  g/dL.  Mean  
corpuscular  volume  increased  by  6.80  +/-  1.88  uM3,  PCV  increased  by  
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<  0.001 
The  final  increase  was  statistically  significant  with  regards  to  all  the  
variables  (<0.001).  ( tab 10) 
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In  the  second  follow  up  visit  at  4  weeks,  children  in  both  groups  
were  examined  for  clinical  improvement  of  anemia,  drug  compliance  and  
adverse  events.  Samples  were  taken  for  hemoglobin  estimation. 
The  mean  hemoglobin  at  the  end  of  four  weeks  of  intermittent  
iron  supplementation  was  9.01gm  /dl  with  a  standard  deviation  of   1.25  
g/dl.   The  mean  raise  in  hemoglobin  observed  was  0.43  g/dl.(Table  11).  
The  mean  hemoglobin  after  four  weeks  of  intervention  in  daily  
supplementation  group  was  9.47  g/dl  with  a  standard  deviation  of  1.32  
g/dl.  The  increase  in  mean  hemoglobin  was  1.0  g/dl.  (Chart  3  &  4) 
 
 
Chart  4:  Comparison  of  follow-up  hemoglobin  both  groups. 
 
 
The  mean  hemoglobin  at  the  end  of  four  weeks  of  intermittent  
iron  supplementation  was  9.01gm  /dl  with  a  standard  deviation  of   1.25  
g/dl.   The  mean  raise  in  hemoglobin  observed  was  0.43  g/dl.(Table  11).  
The  mean  hemoglobin  after  four  weeks  of  intervention  in  daily  
supplementation  group  was  9.47  g/dl  with  a  standard  deviation  of  1.32  


























Intermittent Regimen Daily Regimen
The  study  was  completed  after  12  weeks  of  iron  supplementation  
and  data  collected  from  both  intervention  are  analyzed  using  IBM  SPSS  
statistical  software  version  20.0. 
 




The  final  mean  hemoglobin  concentration  for  the  intermittent  
group    (  n  =  68  )  was  11.81  g/dl  with  a  standard  deviation  of  .45  g/dl.  



























Mean increase in Hemoglobin 
Intermittent Regimen Daily Regimen
deviation  of  1.52  %.  The  mean  final  mean  corpuscular  volume  was  
77.78  µM3   with  a  standard  deviation  of  1.50  µM3  .  The  final  mean  
serum  ferritin  was  24.40  ng/ml  with  a  standard  deviation  of  5.93  ng/ml.   
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In  the  final  assessment  of  Daily  iron  supplementation  group  after  
12  weeks,  hemoglobin  increased  by  a  mean  of  3.52  +/-  0.78  g/dL.  Mean  
corpuscular  volume  increased  by  6.80  +/-  1.88  uM3,  PCV  increased  by  
10.21  +/-  2.19  and  serum  ferritin  increased  by  20.61  +/-  5.19  ng/ml.  
The  final  increase  was  statistically  significant  with  regards  to  all  the  
variables  (<0.001).  ( tab 12) 
 
 




















1 Nausea 16 ( 23.5 %) 25 ( 39.6 % ) p = 0.032 
2 Vomiting 8 ( 11.8 % ) 11 ( 16.9 % ) p = 0.039 
3 Dark stools 3 ( 4.4 % ) 10 ( 15.4 % ) p = 0.033 
4 Constipation 5 ( 7.4 % ) 9 ( 13.8 % ) p = 0.023 
5 Abdominal Pain 3 ( 4.4 % ) 8 ( 12.3 % ) p = 0.048  
6 Diarrhea 3 ( 4.4 % ) 6 ( 9.2 % ) p = 0.269 
  
The  occurrence  of    adverse  effects  like  nausea  (p  =  0.032  ),  
vomiting  (p  =  0.039),  passing  dark  stools  ( p  =  0.033),  constipation  (p  =  
0.023),  abdominal  pain  (p  =  0.048)  were  significantly  more  in  the  Daily  
supplementation  group  as  compared  to  intermittent  group.  However  the  
occurrence  of  diarrhea  was  similar  in  both  groups.  None  of  the  study  
subject  developed  serious  adverse  reactions  like  anaphylaxis,  diplopia  or  
had  encountered  accidental  poisoning. 
 
The adverse effect profile in both the treatment groups are shown 
below. (chart 6 & 7). 








Intermittent Iron Supplementation Group
Nil Nausea Vomiting Dark Stools Constipation Abdominal Pain Diarrhoea
Chart 7:  Profile of adverse effects in Daily  therapy  Group 
  
DISCUSSION 
In  our  Indian  subcontinent,  folic  acid  is  routinely  added  to  iron  
tablets  in  current  national  programs  for  control  of  anemia.  Hemoglobin  
and  Hematocrit  levels  in  groups  supplemented  with  daily  and  weekly  
iron  and  folic  acid  improved  to  an  equal  extent. 
The  characteristics  of  the  both  groups  of  study  population  were  
comparable  in  terms  of   mean  age,  gender  and  initial  hemoglobin  values.   
A  total  of  68  out  of  70   were  able  to  complete  the  therapy  with  
intermittent  biweekly  iron  therapy  whereas  only  65  out  of  70  completed  
therapy  on  daily  therapy. Slightly  improved  patient  acceptability  is  seen  
with  intermittent  supplementation  group  than  with  daily  supplementation 
There  was  no  difference  between  the  children  who  dropped  out  







Daily Iron Supplementation Group
Nil Nausea Vomiting Dark Stools Constipation Abdominal Pain Diarrhoea
hemoglobin  and  serum.  Similarly,  there  was  no  difference  between  the  
children  who  dropped  out  in  the  two  treatment  groups.    
At  the  start  of  the  study,  there  was  no  significant  difference  
between  initial  hemoglobin  concentrations  of  the  two  groups  (  mean  
initial  Hb  of  8.58  +/-  1.07  vs  8.47  +/-  1.01  )  although  mean  
hemoglobin  concentration  of  the  daily  group  was  marginally  lower.  
Similarly,  initial  serum  ferritin  concentrations  of  the  two  groups  did  not  
differ  (10.18  +/-  1.51  vs  10.11  +/-  1.65  ).   
   After  an  average  12  weeks  of  iron  supplementation,  there  was  a  
significant  improvement  in  the  hemoglobin  concentrations  in  both  groups.  
In  the  intermittent  biweekly  group  there  was  an  increase  of  3.22g/dl  of  
hemoglobin  (P  <  0.001);  the  comparative  increase  in  the  daily  group  
was  3.53  g/dl  (P  =  0.001).  On  comparison  of  the  final  hemoglobin  
values  of  both  groups,  there  appears  a  slightly  higher  increase  of  
hemoglobin  in  daily  supplementation  group.  But  the  increase  is  not  
statistically  significant  (p  =  0.190  ),  thus  showing  that  the  outcome  
of  both  regimen  appears  similar. 
Similarly,  the  serum  ferritin  concentrations  in  the  intermittent  
biweekly  therapy  group  increased  by  14.21  μg/L  (P  <  0.001),  whereas  in  
the  daily  supplementation  group  showed  an  increase  of  20.61  μg/L  (P  <  
0.001)  .  Thus,   serum  ferritin  has  increased  statistically  significant  in  
the  daily  group  than  in  the  intermittent  biweekly  group  (  p  <  0.001  
). 
In  the  present  study,  both  intervention  regimens  of  iron  therapy  
(biweekly  intermittent  and  daily)  improved  hemoglobin  levels  and  the  
proportion  of  change  from  baseline  to  end  of  the  intervention  was  found  
to  be  similar.  Similar  to  our  finding,  Kotecha  et  al., 35 in  their  study  
among  adolescent  girls  in  India  reported  that  supervised  once  a  week  
iron-folate  administration  (IFA)  supplementation  in  schools  was  an  
effective  intervention  to  reduce  anemia.  Agarwal  et  al.  in  their  study  on  
adolescent  girls  in  India  concluded  that  regular  weekly  iron-folic  
administration  was  effective  and  suitable  for  treating  mild  to  moderate  
anemia.36 
We  observed  that  statistically  significant  increase  in  mean  
hemoglobin  levels  in  the  daily  therapy  than  with  intermittent  therapy.      
In  our  study,  the  increment  in  serum  ferritin  was  statically  
significant    in  the  daily  iron  supplementation  groups  than  with  
intermittent  supplementation.  Similar  to  our  finding,  studies  by  
Sungthong  et  al., 37 reported  higher  serum  ferritin  in  school  children  













CONCLUSIONS   
 The  result  of  this  study  has  demonstrated  that  results  of  
intermittent  iron  therapy  have  a  similar  response  in  increasing  
hemoglobin  hematocrit  and  red  cell  indices  like MCV  compared  to  its  
daily  administration,  however the increase in serum ferritin was significantly  
better in the daily supplementation group.  Further,  biweekly  administration  
of   iron  along  with  folic  acid  has  improved  drug  compliance  and  fewer  
adverse  reactions  than  with  daily  administration. 
Hence  it  is  concluded  that  intermittent  (  biweekly  )  iron  therapy   
is  an  effective  alternative  to  daily  administration.  A  simple  and  
inexpensive  programs  of  biweekly  iron  supplementation  can  be  used  in  
public  healthcare  clinics  or  at  home  to  effectively  reduce  the  prevalence  
of  iron-deficiency  anemia.   
The  results  showed  that  the  program  of   intermittent  iron  therapy  
described  in  this  study  fulfilled  the  requirements  of  providing  easily  
administered  iron  supplementation  involving  minimal  human  resources  at  




   
RECOMMENDATIONS   
In  developing  countries,  hematinic  supplements  are  distributed  
through  the  primary  health  care  systems.  However,  sustained  efficacy  is  
uncommon,  owing  to  factors  such  as  irregular  tablet  distribution  and  
poor  compliance.  Thus  less-frequent  schedule  would  mean  less  cost  and  
better  compliance.   
Hence  we  recommend  that  policy  makers  adapt  intermittent  
regimens  to  tide  over  the  major  public  health  problem  of  iron  deficiency  
anemia. 
In  infants  and  preschool  children,  biweekly  supplementation  
through  Anganwadi  and  RCH  programs  will  lowers  the  prevalence  of  










1. The  study  is  not  double  blinded. 
2. The  study  was  done  using  ferrous  sulphate  as  the  iron  preparation.  
Hence  the  effect  of  other  iron  preparations  cannot  be  extrapolated  
with  this  study. 
3. Study  is  focused  only  on  children  of  age  6  months  to  5  yrs.  
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மருத்துவமதை எண்: 
              
                        இந்ை மருத்துவ ஆய்வின் விவரங்கள் எைக்கு விளக்கப்பட்டது. எைது 
சந்மைகங்கதள தீர்க்கவும் அைற்காை ைகுந்ை விளக்கங்கதள சபைவும் 
வாய்ப்பளிக்கப்பட்டது.  
                     நான் இந்ை ஆய்வின் ைனிச்சியாகைான் பங்மகற்கிமைன். எந்ை காரணத்திைாலும் 
எந்ை கட்டத்திலும் சட்ட சிக்கலின்றி இந்ை ஆய்வின் இருந்து விலகிக்சகாள்ளலாம் என்று 
அறிந்து சகாண்மடன். 
                     நான் ஆய்வின் இருந்து விலகிக்சகாண்டாலும் ஆய்வாளர் எைது மருத்துவ 
அறிக்தககதள பார்ப்பைற்மகா அல்லது பயன்படுத்துவைற்மகா என் அனுமதி 
மைதவஇல்தல என்பதை அறிந்து சகாண்மடன். என்தை பற்றிய ைகவல்கள் ரகசியமாக 
பாதுகாக்கப்படும் என்பதை அறிமவன்.  
                     இந்ை ஆய்வின் மூலம் கிதடக்கும் ைகவல்கள்களும் பரிமசாைதை முடிவுகளும் 
ஆய்வாளர் அவர் விருப்பத்திற்மகற்ப பயன் படுத்திக்சகாள்ளவும் அைதை பிரசுரிக்கவும் 
முழு மைதுடன் சம்மதிக்கிமைன். 
                     இந்ை ஆய்வின் பங்குசகாள்ள சம்மதிக்கிமைன். எைக்கு சகாடுக்கபட்ட 
அறிவுதரகளின்படி நடந்துசகாள்ளவதுடன் ஆய்வாளருக்கு உண்தமயுடன் இருப்மபன் 
என்று உறுதி அளிக்கிமைன்.  
                     உடல்நலம் பாதிக்கபட்டால் அைதை சைரிவிப்மபன் என்று உறுதி அளிக்கிமைன். 
இந்ை ஆய்வின் எைக்கு எந்ை விைமாை பரிமசாைதைகதளயும் சிகிச்தசதகக்கும் 
























ந ோயோளின் தகவல் தோள் 
                 இரும்பு சத்து குறைபாடல் ஏற்படும் இராத்த சசாறை ச ாய் சிகிச்றசக்கு, தினமும் 
மற்றும் இறடவிட்டு இரும்பு சத்து மருந்து கைாடுக்கும் முறைைறை திைறன ஒப்பிடும் 
சசாதறன. 
ஆராய்ச்சியின் ச ாக்ைமும், ஆதாயங்ைளும்: 
                நம்மிதடமய இரும்பு சத்து குதைபாடல் ஏற்படும் இரத்ைமசாதக மநாய் அதிக 
அளவில் காணப்படுகிைது. இதை குணப்படுத்ை சகாடுக்கப்படும் இரும்பு சத்து மருந்து 
பக்க விதளவுகதள ஏற்படுத்துகிைது. இந்ை மருந்திதண இதடசவளி விட்டு 
பயன்படுத்தும் மபாதும் திைமும் பயன்படுத்தும் பலதை அளிப்பைாக சில ஆராய்ச்சிகள் 
சைரிவிக்கின்ைை. இது குழந்தைகளிலும் நிருபைம் ஆைால் அதிக பக்கவிழுவுகள் இன்றியும் 
எளிைாகவும் இந்ை முதைதய பயன்படுத்தி பலன் அதடயாளம். 
ஆய்வு முறை: 
                இதில் உங்கள் குழந்தையின் குருதில், இரும்பு சத்து மருத்துவ சிகிச்தச 
சகாடுப்பைற்கு முன்பும் பின்பும், இரத்ைமசாதக மநாய்க்காண அளவீடுகளாை 
ஹீமமாகிமலாப்பின், சபர்ரிடின் உட்பட அதைத்து மைதவயாை முக்கிய பரிமசாைதைகள் 
சசய்யப்படும். 
உண்டாைக்கூடிய இடர்ைள்: 
                   உங்கள் குழந்தையிடம் இருந்து மூன்று முதை 3 மிலி இரத்ைம் எடுக்கப்படும். 
மமலும் இரத்ைமசாதக மநாய்க்காண சிகிச்தசகாக இரும்பு சத்து மருந்து 
பரிந்துதரக்கப்பட்ட அளவில் பயன்படுத்தும் மபாது, வாந்தி, வயிர் எரிச்சல் மபான்று 
அைற்குண்டாை பக்கவிதளவுகள் ஏற்பட வாய்ப்புள்ளது.  
ஆய்வில் உங்ைள் உரிறமைள்: 
                   உங்கள் மருத்துவ பதிமவடுகள் அந்ைரங்கமாக தவத்துக்சகாள்ளப்படும். இந்ை 
ஆய்வின் முடுவுகள் அறிவியல் பத்திரிதககளில் சவளியிடப்படலாம். இதில் உங்கள் 
சபயமரா அல்லது சசாந்ை ைகவல்கள் சவளி வராது. ஆய்வில் பங்மகற்பது ைனிசியாைது 
மற்றும் காரணம் ஏதும் கூைாமமல நீங்கள் எப்மபாது மவண்டுமாைாலும் 
விலகிக்சகாள்ளலாம். எதுனும் பக்க விதளவுகள் ஏற்பட்டால் முழு சிகிச்தசயும் மருத்துவ 
குழுவிைரால் வழங்கப்படும். 
 
நாள்                                          மநாயாளின் தகசயாப்பம் 



































































































































1 RAKESH M 23 A 7.8 0.5 71 21 8.5 1.7 8.7 11.7 14.5 79 34 YES no no no no no 
2 POOJA  F 14 D 8.2 2.5 71 25 9 3.1 9.6 12.1 23 79 36 no no no no no no 
3 ARCHANA F 36 D 10.8 1.3 72 31 12.5 2.65 11.2 12.5 32.5 77 37 no no no no no no 
4 KARTHICK M 28 A 7.2 0.7 70 22 8.5 1.9 7.8 11.6 23 76 34 no YES no no YES no 
5 FARAHANA F 43 D 9.6 1.2 72 28 11 2.3 10.3 12.1 33 77 36 YES YES no no no no 
6 IMARN M 26 A 8.4 0.8 71 25 11 2.1 9.1 11.9 23.5 78 36 no no no YES no no 
7 KANIMOZHI F 48 D 7.2 0.9 70 22 8 2.6 9.9 11.9 35 78 36 no no no no no no 
8 RANJITH M 16 A 8.5 1.2 71 26 9.5 2.2 8.6 12.1 26 76 36 YES no no no no no 
9 PRIYA F 12 A 10.2 0.8 72 32 12 2 10.2 12.6 22 76 37 no no YES no no no 
10 RAMESH 
KRISHNA 
M 17 A 7.9 0.9 72 24 9 2.1 8.1 11.8 26.4 78 35 no no no no no no 
11 ANJALI F 49 D 8.3 0.85 71 25 8 3.1 9.3 11.9 45.5 77 36 no no no no no no 
12 RESHMA F 34 D 9.7 0.75 71 28 9.5 3.2 10.7 12.2 26 76 37 no no no no no no 
13 ARUN M 56 D 7.2 0.6 69 23 8 2.1 9.2 11.8 27 79 35 YES no no YES no no 
14 FARHANA F 21 A 9.8 1.2 71 30 11.5 2.3 10 12.3 26 80 37 no YES no no no YES 
15 PRATHISH M 17 A 7.1 1.3 69 22 9 2.5 8.6 10.8 14 75 32 YES no no no no no 
16 MRITHULA F 38 A 8.6 1.1 70 26 11 2.05 8.7 12 21 79 36 no no no YES no no 
17 MUSHARAF M 42 D 9.4 0.75 71 28 11 2.4 10.3 12.4 28.5 77 37 no no no no no no 
18 IMRAN M 27 D 7.3 1.2 71 22 8 2.1 9.9 11.6 31 76 35 no YES no no no YES 
19 KAMALESHWARI F 7 A 10.6 0.6 72 32 12 1.8 10.7 12.8 31.5 76 33 no no no no no no 
20 SANJAY M 31 D 8.3 1.5 72 26 10.5 2.2 10.4 11.9 32.5 79 36 no no YES no no no 
21 SARANYTA F 52 A 7.9 0.95 71 23 10 2.1 8.1 11.4 28 78 34 no no no no no no 
22 POOJA  F 18 D 9.2 1.7 72 29 11 2.5 10.6 12.1 28 77 36 YES no no no no no 
23 ELAMRAN M 60 A 8.7 0.75 72 25 9.5 2.3 8.8 12.1 22.5 76 36 YES no no no no no 
24 SEETHA F 35 D 7.3 1.3 70 23 9 2.1 8.9 11.8 31 77 35 no no no no no no 
25 ELUMALAI M 53 D 10.4 1 73 31 12.5 2.35 11.2 11.7 25 78 35 no YES no no no no 
26 RAJESH M 22 D 7.2 1.2 71 22 7.5 2.6 8.6 11.8 23 77 35 YES no no YES YES YES 
27 HASINI F 47 A 8.8 0.65 72 25 9 2.6 8.9 12.3 22 80 37 no YES no no no no 
28 SUDHA F 36 A 7.4 1.25 71 23 8 2.1 8.4 11.6 19.5 79 34 no no no no no no 
29 AJAY M 16 D 9.6 1.3 72 29 11 2.5 9.9 12.3 43.5 79 37 no no YES no no no 
30 VASANTHI F 41 D 8.1 1.5 71 26 10 2.9 8.9 12.1 33 78 36 YES no no no no no 
31 KATRTHIKA F 18 D 7.5 1.6 71 23 9.5 2.1 8.8 11.3 30 77 34 no no no no no no 
32 DHIYA F 11 A 7.1 1.2 68 22 8.5 2.3 8.2 10.6 14 78 31 no no no no no no 
33 VIJAY M 32 D 8.4 1.7 70 25 10 3.2 9.2 11.8 28.5 79 35 YES no no no no no 
34 KISHORE M 51 A 9.3 0.8 71 30 11 2.95 9.4 12.2 24.5 76 37 YES no no no YES no 
35 SRIJA F 14 D 8.4 1.5 70 25 11.5 2.1 9.3 12.4 32 79 37 no no YES no no no 
36 TIRUPATHI M 44 A 7.2 0.9 69 22 8 2.1 8.6 11.9 19 80 36 no YES no no no no 
37 ARUNA F 19 D 10.2 1.2 72 31 12 2.55 10.8 12.4 29 77 37 no YES no no no no 
38 SAMEER M 59 A 8.3 0.75 72 24 9.5 2.15 8.3 11.8 21.5 75 36 no no no no no no 
39 SANGEETHA F 9 A 9.7 0.6 72 30 12 1.95 8.8 12.3 27 79 37 YES no YES no no no 
40 KANNAN M 16 D 7.3 1.3 70 22 13 2.85 8.8 11.3 43.5 78 34 YES no no YES YES no 
41 VIDHYA F 58 A 9.4 0.85 72 29 11.5 2.1 9.5 12.2 34.5 79 37 no no no no no no 
42 RADHA F 29 A 7.8 0.7 70 24 9 2.1 8.2 11.8 16 76 36 no YES no no no no 
43 MALA F 39 D 8.2 1.5 71 25 9.5 3.1 9.2 12.3 35 79 37 no no no no no no 
44 ARULKUMAR M 54 D 7.7 1.2 69 23 7 2.85 8.4 11.7 15 78 35 YES no no no no YES 
45 TRISHA F 20 A 8.6 0.85 71 26 10 2.15 8.7 12.2 28.5 79 37 YES no no no no no 
46 SAKTHIVEL M 19 A 10.2 0.95 72 31 12.5 2.35 10.3 12.4 26 78 37 no YES no no no YES 
47 KUMARAN M 35 D 8.3 0.8 71 25 10 2.9 8.5 12.1 31.5 79 36 no YES no no no no 
48 ABIRAMI F 28 A 7.2 1.5 69 22 8 2.1 8.2 11.2 19 80 34 no no no no no no 
49 KARTHICK M 57 A 9.4 1.2 72 30 13.5 2.25 9.5 12.1 30 80 36 YES no no no no no 
50 SANMATHI F 30 A 8.4 1.7 70 25 10 1.95 8.5 11.6 28.4 75 34 no no YES no no no 
51 SUPRIYA F 45 D 7.1 0.95 70 21 7.5 2.1 8.2 10.8 26 76 31 YES no YES no no no 
52 KALAIYARASI F 10 A 8 1.4 70 24 10 2.1 8.5 12.1 34 76 36 no YES no no no no 
53 KAMILL M 20 D 7.9 0.75 70 24 11 2.3 8.6 11.7 33.5 78 35 no no no no no no 
54 JAYANTHI F 16 D 10.2 0.95 71 31 12 2.1 10.7 12.9 31.5 79 39 no no no no no no 
55 AJEEZ M 22 A 7.5 1 70 23 8.5 2.3 8.2 11.3 15 76 34 no no no YES no no 
56 HARINI F 50 A 10.7 1.2 73 32 12 2.5 10.9 12.5 33 78 37 YES no no no no no 
57 KARTHICKUMAR M 44 D 8.4 0.9 80 26 10.5 2.6 9.2 12.4 31 79 37 YES no no no YES no 
58 MURALI M 37 A 9 1.4 70 28 10.5 2 9.5 11.9 19.4 77 36 no YES no no no no 
59 SRIPRIYA F 20 A 7.6 1.9 69 23 8 2.85 8.4 11.8 21 79 35 no no no no no no 
60 MOHAN M 41 D 9.1 0.85 71 28 11 2.3 9.5 12.6 29 80 38 no YES no YES no no 
61 ANADHI F 8 D 7 0.9 68 22 7.5 2.65 8.3 10.7 28 77 32 YES no YES no no no 
62 CHANDER M 14 A 8.3 2 71 25 12 1.2 8.7 11.6 21.5 78 35 YES no no no no no 
63 MEENA F 36 D 9.3 1.2 70 28 10 2.35 9.9 11.8 34.5 76 35 no no no no no no 
64 JEEVAN M 52 D 10.1 1.3 71 30 12.5 2 10.5 13.1 39 79 39 YES no no no no no 
65 VIGNESH M 34 A 8.3 1.2 71 24 12.5 1.9 8.6 11.7 20 79 35 no no no no YES no 
66 NIRANCHANA F 17 D 7.4 1.4 71 22 7 3.45 7.9 11.9 33 80 36 no no no no no no 
67 MAGESH M 50 A 9.4 1.3 72 29 11 2.1 9.8 12.1 29.5 77 36 no no no no no no 
68 BALA M 33 D 7.6 1.6 71 23 8 2.2 8.2 11.6 29 79 35 no YES no no no no 
69 LEELA F 49 D 8.7 0.75 71 25 9.5 2.65 9.7 12.4 34.3 78 37 YES no YES YES YES no 
70 VINOD M 19 A 7.2 1.25 71 23 8 2.2 7.7 11.2 21 77 33 YES no no no no no 
71 ARCHANA F 43 D 10.3 0.95 72 31 12 2.45 10.9 12.6 26 79 38 no no no no no no 
72 SUGASINI F 19 D 8.2 1.2 71 25 9 2.1 9.3 12.1 39 76 36 no YES no no no no 
73 JEGAN M 42 A 7.6 0.75 71 23 9 1.9 8.1 11.4 21 78 34 no no no no no no 
74 REKHA F 15 D 9.2 1.3 71 28 9 2.7 10.3 12.3 28.5 77 37 no no YES no no YES 
75 SATISH M 54 A 8.5 0.85 72 26 10.5 1.85 8.9 11.9 14 79 36 no no no no no no 
76 PRATHIBA F 20 D 7.8 1.3 71 24 7.5 2.55 8.9 11.4 29 76 34 YES no no no no no 
77 VIDHYA F 45 D 8.9 1.4 72 27 9 3.1 9.9 11.9 31.3 75 36 no no no no no no 
78 CHRITOPHER M 25 A 7.6 1.2 71 23 9 2.15 8 11.4 22.5 79 34 YES no no no no no 
79 NAVEEN M 7 A 9.7 1.3 71 29 9.5 2.1 10.2 12.1 29 80 36 no no no YES no no 
80 NIMMY F 21 D 8.3 1.5 71 26 9.3 2.85 9.4 12.4 28 75 37 no YES no no YES no 
81 PERUMAL M 12 D 7.3 1.25 70 23 7.4 2.7 8.4 11.8 30 78 35 YES no YES YES no no 
82 RESHMA F 54 A 8.4 1.45 71 25 10 2.3 8.7 11.9 19 77 36 no no no no no no 
83 NIRMAL M 30 A 7.1 1.75 69 21 10 2.45 7.9 10.7 15.5 78 31 YES no no no no no 
84 FATHIMA F 16 A 10.3 1.3 73 31 12.5 2.1 10.7 12.5 34 79 37 no no no no no no 
85 SULTANA F 54 A 8.2 0.9 72 24 10 2 8.7 11.6 22.5 77 35 no no no no no no 
86 KATHIR M 38 D 7.9 1.55 70 23 9 2.35 9.1 12.1 31.5 78 36 YES no no no no no 
87 MUTHU M 27 A 9.8 0.75 72 31 11 2.3 10.3 11.9 19 78 36 YES no no no no no 
88 JESSICA F 24 A 7.1 0.85 72 22 9.5 2 7.7 11.3 22 79 34 no no no no no no 
89 MARY F 41 D 8.3 0.6 70 24 10 2.6 9.3 12.4 36 77 37 no YES no no no no 
90 SARAVANAN M 52 D 10.4 0.8 72 31 12.5 2.8 11.1 12.9 31 79 39 YES no no no no no 
91 LAKSHMI F 25 A 9.7 1.35 71 30 12 1.9 9.5 12.2 33 78 36 YES no no no no no 
92 ISAC M 32 A 7.3 1.2 71 22 7 2.1 7.5 11.1 15.5 79 33 no no no no no no 
93 PREETHI F 50 D 8.7 0.75 71 26 11.5 2.45 9.3 11.9 29.4 75 36 no no no no no no 
94 ISHWARYA F 11 D 9.2 0.55 70 28 12 2.1 9.9 11.8 34 78 35 no YES no no YES no 
95 MUMTAJ F 44 D 7.8 0.8 70 23 7 2.9 8.6 11.9 26 78 36 YES no YES YES no no 
96 VIVEK M 20 A 8.4 1.6 71 25 10 2.3 8.9 11.8 25 79 35 no no no no no no 
97 POOJITHA F 24 A 9.9 1.2 72 30 9.3 1.9 10.3 12 34 80 36 no no no no no YES 
98 FYAZ M 47 D 7.3 0.9 69 23 10.5 2.75 8.4 11.8 21.5 77 35 no no no no no no 
99 ISABELL F 60 A 10.8 1.35 73 33 12 1.85 11.2 12.2 37.5 78 36 no no no YES no no 
100 RAKESH M 27 A 7.3 0.95 71 23 8 2.1 7.9 11.6 29 77 34 YES no no no no no 
101 HARITHA F 19 D 8.2 1.2 70 25 11 2.45 9.3 12.7 32 76 37 YES no no no no no 
102 CHELLADURAI M 10 D 7.9 1.2 70 24 11 2.1 9.1 12.1 36 78 36 no no YES no no no 
103 ARTHI F 34 A 8.8 0.8 72 27 12 2.25 9.3 11.9 30 76 36 no no no no no no 
104 SUBAHSINI F 36 D 9.1 1.3 71 27 12.5 2.1 10.1 11.9 32.6 75 35 YES no no no no YES 
105 MANOJ M 18 D 7 1.4 70 21 10.4 2.6 7.7 11.2 21.5 78 33 no no no YES no no 
106 SRIVARSHAN M 13 A 9.3 1.35 72 28 11 2.1 9.7 11.8 23 79 35 no no no no no no 
107 KANISHA F 42 D 8.6 0.9 71 26 12 2.7 9.7 12.1 26 76 36 no no no no no no 
108 SINDHUJA F 28 A 7.1 1.75 69 21 7.5 2.35 7.6 10.8 32.5 75 32 no no no no no no 
109 NISHANTH M 25 A 10.6 1.25 71 32 12 2.3 10.9 12.1 27.5 78 36 no no no no no no 
110 BHARGAVI F 38 D 9.3 0.85 71 29 11.5 2.1 10.2 12.4 26 79 37 YES no no no no no 
111 AMALA F 8 D 9.8 0.75 72 30 12 2.5 10.6 12.3 37 78 37 no no no no YES no 
112 KAMALESH M 24 A 8.2 1.4 71 25 11 2.4 9.2 11.6 29 78 35 no no no no no no 
113 ANUPRIYA F 17 D 7.7 0.8 71 23 10 2.45 8.6 11.6 28 79 35 no no no no no no 
114 EDWIN M 48 A 9.4 1.7 71 29 12 2.3 9.9 11.9 22 79 36 no no no no no no 
115 ARUNTHAMIL M 32 A 8.6 1.2 71 26 10.5 2.1 8.9 11.7 26 79 35 no no no no no no 
116 ANUSHA F 18 A 10.4 0.8 72 32 12 2.5 10.7 12.1 27.5 80 36 no no no no no no 
117 MULLAI F 37 A 7.2 0.65 70 23 7 2.1 7.4 11.1 28 76 33 no no no no no no 
118 KUMARESH M 29 A 9.7 1.4 71 30 11 2.5 9.7 11.8 22.5 77 35 no no no no no no 
119 RAGHU M 43 D 8.3 1.25 72 25 12.5 3.85 9.2 11.6 29.7 77 35 YES no no no no no 
120 KANIMOZHI F 25 D 9.6 1.6 71 29 11.5 2.9 10.6 12.3 37 78 37 no no no no YES no 
121 AMNURADHA F 35 D 7.4 1.3 70 23 10 2.65 8.2 11.8 25 79 36 YES no no no no no 
122 PRABHA F 12 A 8.2 0.7 71 24 11.5 2.1 8.7 11.7 21 75 35 no no no no no no 
123 HARSHINI F 26 D 9.1 1.2 70 27 11 2.7 9.8 12.1 35 80 36 no no no no no no 
124 BALAGI M 48 D 7.6 1.45 71 23 10.5 2.1 8.3 11.7 23.5 77 35 no no no no no no 
125 AKILA F 60 A 8.3 0.85 71 26 10 2.6 8.8 11.5 28.5 76 34 no no no no no no 
126 JAYASANKAR M 30 A 9.2 0.9 72 28 11 2.1 9.6 11.9 25 77 36 no no no no no no 
127 ILAVARASI F 39 A 7.9 1.6 70 24 9.5 2.1 8.4 11.4 15 78 34 no no no no no no 
127 JAYANTHAN M 48 D 9.3 1.2 72 28 11 2.75 10.2 11.9 31 79 36 no no no no no no 
129 RAMYA F 24 D 8.6 1.5 71 26 10 2.55 9.9 11.6 34 78 35 no no no YES no no 
130 ISAIPRIYA F 11 D 7.2 1.3 70 23 9.5 3.1 8.7 11.8 31 79 35 YES no no no no YES 
131 POOVIKA F 16 A 8.1 1.8 71 24 10 2.35 8.6 11.9 24 76 36 no no no no no no 
132 SANDEEP M 25 A 9.1 1.2 71 27 10.5 2.1 9.9 12.6 36.5 79 38 no no no no no no 
133 VENNILLA F 30 A 8.7 1 71 26 10 2.15 9.7 12.2 26 78 37 no no no no no no 
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                        இந்ை மருத்துவ ஆய்வின் விவரங்கள் எைக்கு விளக்கப்பட்டது. எைது 
சந்மைகங்கதள தீர்க்கவும் அைற்காை ைகுந்ை விளக்கங்கதள சபைவும் வாய்ப்பளிக்கப்பட்டது.  
                     நான் இந்ை ஆய்வின் ைனிச்சியாகைான் பங்மகற்கிமைன். எந்ை காரணத்திைாலும் எந்ை 
கட்டத்திலும் சட்ட சிக்கலின்றி இந்ை ஆய்வின் இருந்து விலகிக்சகாள்ளலாம் என்று அறிந்து 
சகாண்மடன். 
                     நான் ஆய்வின் இருந்து விலகிக்சகாண்டாலும் ஆய்வாளர் எைது மருத்துவ 
அறிக்தககதள பார்ப்பைற்மகா அல்லது பயன்படுத்துவைற்மகா என் அனுமதி மைதவஇல்தல 
என்பதை அறிந்து சகாண்மடன். என்தை பற்றிய ைகவல்கள் ரகசியமாக பாதுகாக்கப்படும் 
என்பதை அறிமவன்.  
                     இந்ை ஆய்வின் மூலம் கிதடக்கும் ைகவல்கள்களும் பரிமசாைதை முடிவுகளும் 
ஆய்வாளர் அவர் விருப்பத்திற்மகற்ப பயன் படுத்திக்சகாள்ளவும் அைதை பிரசுரிக்கவும் முழு 
மைதுடன் சம்மதிக்கிமைன். 
                     இந்ை ஆய்வின் பங்குசகாள்ள சம்மதிக்கிமைன். எைக்கு சகாடுக்கபட்ட 
அறிவுதரகளின்படி நடந்துசகாள்ளவதுடன் ஆய்வாளருக்கு உண்தமயுடன் இருப்மபன் என்று 
உறுதி அளிக்கிமைன்.  
                     உடல்நலம் பாதிக்கபட்டால் அைதை சைரிவிப்மபன் என்று உறுதி அளிக்கிமைன். 
இந்ை ஆய்வின் எைக்கு எந்ை விைமாை பரிமசாைதைகதளயும் சிகிச்தசதகக்கும் மமற்சகாள்ள 
























ந ோயோளின் தகவல் தோள் 
                 இரும்பு சத்து குறைபாடல் ஏற்படும் இராத்த சசாறை ச ாய் சிகிச்றசக்கு, தினமும் 
மற்றும் இறடவிட்டு இரும்பு சத்து மருந்து கைாடுக்கும் முறைைறை திைறன ஒப்பிடும் 
சசாதறன. 
ஆராய்ச்சியின் ச ாக்ைமும், ஆதாயங்ைளும்: 
                நம்மிதடமய இரும்பு சத்து குதைபாடல் ஏற்படும் இரத்ைமசாதக மநாய் அதிக 
அளவில் காணப்படுகிைது. இதை குணப்படுத்ை சகாடுக்கப்படும் இரும்பு சத்து மருந்து பக்க 
விதளவுகதள ஏற்படுத்துகிைது. இந்ை மருந்திதண இதடசவளி விட்டு பயன்படுத்தும் 
மபாதும் திைமும் பயன்படுத்தும் பலதை அளிப்பைாக சில ஆராய்ச்சிகள் சைரிவிக்கின்ைை. 
இது குழந்தைகளிலும் நிருபைம் ஆைால் அதிக பக்கவிழுவுகள் இன்றியும் எளிைாகவும் இந்ை 
முதைதய பயன்படுத்தி பலன் அதடயாளம். 
ஆய்வு முறை: 
                இதில் உங்கள் குழந்தையின் குருதில், இரும்பு சத்து மருத்துவ சிகிச்தச சகாடுப்பைற்கு 
முன்பும் பின்பும், இரத்ைமசாதக மநாய்க்காண அளவீடுகளாை ஹீமமாகிமலாப்பின், சபர்ரிடின் 
உட்பட அதைத்து மைதவயாை முக்கிய பரிமசாைதைகள் சசய்யப்படும். 
உண்டாைக்கூடிய இடர்ைள்: 
                   உங்கள் குழந்தையிடம் இருந்து மூன்று முதை 3 மிலி இரத்ைம் எடுக்கப்படும். 
மமலும் இரத்ைமசாதக மநாய்க்காண சிகிச்தசகாக இரும்பு சத்து மருந்து பரிந்துதரக்கப்பட்ட 
அளவில் பயன்படுத்தும் மபாது, வாந்தி, வயிர் எரிச்சல் மபான்று அைற்குண்டாை 
பக்கவிதளவுகள் ஏற்பட வாய்ப்புள்ளது.  
ஆய்வில் உங்ைள் உரிறமைள்: 
                   உங்கள் மருத்துவ பதிமவடுகள் அந்ைரங்கமாக தவத்துக்சகாள்ளப்படும். இந்ை 
ஆய்வின் முடுவுகள் அறிவியல் பத்திரிதககளில் சவளியிடப்படலாம். இதில் உங்கள் சபயமரா 
அல்லது சசாந்ை ைகவல்கள் சவளி வராது. ஆய்வில் பங்மகற்பது ைனிசியாைது மற்றும் 
காரணம் ஏதும் கூைாமமல நீங்கள் எப்மபாது மவண்டுமாைாலும் விலகிக்சகாள்ளலாம். 
எதுனும் பக்க விதளவுகள் ஏற்பட்டால் முழு சிகிச்தசயும் மருத்துவ குழுவிைரால் 
வழங்கப்படும். 
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